[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 464
1. Byun TJ, Han DS, Ahn SB, Cho HS, Eun CS, Jeon YC, Sohn JH, Oh YH: Pseudoinvasion in an adenomatous polyp of the colon mimicking invasive colon cancer. Gut Liver; 2009 Jun;3(2):130-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudoinvasion in an adenomatous polyp of the colon mimicking invasive colon cancer.
  • Pseudoinvasion or pseudocarcinomatous invasion in an adenomatous polyp of the colon can be unfamiliar to an endoscopist.
  • Pseudoinvasion in an adenomatous polyp represents prolapse of the adenomatous epithelium into its stalk.
  • In most cases its morphology does not differ from of general adenomatous polyps, but in some cases it can morphologically mimic a malignant polyp with submucosal invasion due to mass-like lesioning of its stalk.
  • This makes it difficult for endoscopists to differentiate pseudoinvasion in an adenoma from an invasive carcinoma by conventional endoscopy; instead, endoscopic ultrasonography can provide useful information for differentiating these conditions.
  • We report on an 82-year-old man who presented with a large pedunculated polyp with a thick stalk in the sigmoid colon, which mimicked a submucosal invasive carcinoma.
  • The patient was diagnosed with pseudoinvasion in an adenomatous polyp after segmental resection of the sigmoid colon.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1973 Jan;26(1):25-31 [4540378.001]
  • [Cites] Cancer. 1974 Jan;33(1):206-17 [4810096.001]
  • [Cites] Dis Colon Rectum. 1980 Nov-Dec;23(8):529-35 [7460689.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):709-18 [11490390.001]
  • [Cites] Adv Anat Pathol. 2008 Jan;15(1):1-17 [18156808.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):722 [12709708.001]
  • [Cites] Pathol Int. 2003 Sep;53(9):584-90 [14507314.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):1-7 [15672048.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):206-15 [11812942.001]
  • (PMID = 20431736.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2852693
  • [Keywords] NOTNLM ; Adenomatous polyps / EUS / Malignant polyp / Pseudoinvasion
  •  go-up   go-down


2. Castillo-Alcala F, Mans C, Bos AS, Taylor WM, Smith DA: Clinical and pathologic features of an adenomatous polyp of the colon in a domestic ferret (Mustela putorius furo). Can Vet J; 2010 Nov;51(11):1261-4
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and pathologic features of an adenomatous polyp of the colon in a domestic ferret (Mustela putorius furo).
  • A 6-year-old castrated male domestic ferret (Mustela putorius furo) with a 4-week history of intermittent diarrhea and straining during defecation had an intraluminal mass in the descending colon identified by abdominal ultrasound.
  • The histopathological diagnosis of the resected mass was an adenomatous polyp of the colon.
  • [MeSH-major] Adenomatous Polyps / veterinary. Colonic Polyps / veterinary. Ferrets

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Anim Hosp Assoc. 1997 Mar-Apr;33(2):156-60 [9111726.001]
  • [Cites] J Am Vet Med Assoc. 1998 May 1;212(9):1402-6 [9589126.001]
  • [Cites] Vet Surg. 2006 Jun;35(4):337-40 [16756613.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2551-7 [17167138.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • (PMID = 21286327.001).
  • [ISSN] 0008-5286
  • [Journal-full-title] The Canadian veterinary journal = La revue vétérinaire canadienne
  • [ISO-abbreviation] Can. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2957035
  •  go-up   go-down


3. Lee HL, Son BK, Lee OY, Jeon YC, Han DS, Sohn JH, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH, Kee CS: [Abdominal obesity, insulin resistance, and the risk of colonic adenoma]. Korean J Gastroenterol; 2007 Mar;49(3):147-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdominal obesity, insulin resistance, and the risk of colonic adenoma].
  • BACKGROUND/AIMS: Abdominal obesity and hyperinsulinemia or insulin resistance are of interest in connection with colon carcinogenesis.
  • We conducted a prospective case controlled study for the evaluation of relationship between abdominal obesity, insulin resistance, and colorectal adenoma.
  • METHODS: Fifty patients with colorectal adenoma and fifty healthy subjects were included in this study.
  • RESULTS: There were no differences in sex, serum insulin, FBS, HOMA-IR, TG, CROL between adenoma and control group.
  • Subjects with high BMI, WHR, percent body fat, and obesity were more likely to have colonic adenoma.
  • Multiple logistic regression analysis after adjusting confounding factors, had revealed that WHR was the most important independent risk factor for colon adenoma.
  • CONCLUSIONS: Abdominal obesity was most closely related to colonic adenoma.
  • However, insulin resistance was not related to colonic adenoma.
  • [MeSH-major] Abdominal Fat. Adenoma / etiology. Colonic Neoplasms / etiology. Insulin Resistance. Obesity / complications

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2007 Mar;49(3):192-5 [18172350.001]
  • (PMID = 18172342.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


Advertisement
4. Militsa NN, Postolenko ND, Kotelevets VV, Lazareva NV: [Successful operative treatment of multiple intestinal invagination, caused by adenomatous polyp of colon transversum]. Klin Khir; 2008 Jun;(6):57-8
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful operative treatment of multiple intestinal invagination, caused by adenomatous polyp of colon transversum].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18982730.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


5. Ji JH, Park BJ, Park YS, Hwang JH, Chung SH, Kim N, Lee DH, Jung HC, Song IS: [Clinicopathologic study of colorectal polyps and obesity in Korean adult]. Korean J Gastroenterol; 2007 Jan;49(1):10-6
MedlinePlus Health Information. consumer health - Obesity.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of colorectal polyps and obesity in Korean adult].
  • Numerous epidemiologic studies have shown a positive association between obesity and colorectal polyps.
  • There are few studies investigating the association between colorectal adenomatous polyps and body fat composition in Korea.
  • We tried to examine the relationship between body fatness and colorectal adenomatous polyps in health check-up subjects in Korea.
  • METHODS: Six thousand seven hundred and six routine health check-up subjects, who visited our hospital between March 2002 and April 2005 and underwent distal colon examimation with sigmoidoscopy, were enrolled in this study.
  • Among them, colonoscopy was done in 860 patients to evaluate the entire colon.
  • We tried to reveal the relationship between body mass index (BMI) and size, location, number and histopathological type of polyps.
  • RESULTS: The mean value of BMI in total polyp-free group (23.8+/-2.9) was not different from that of the polyp group (24.5+/-2.8, p=0.09).
  • The frequency of rectosigmoid polyps in obese patients (20.4%) was higher than that in non-obese patients (16.0%, p<0.05).
  • The frequency of adenomatous polyp was not different between obese and non-obese group.
  • Number of polyps (> or=4) correlated well with obesity.
  • Moreover, age and triglyceride level in patients with colonic adenoma were significantly higher than in patients without colonic adenom.
  • CONCLUSIONS: This study shows that obesity is not associated with colonic adenomatous polyp in Korean population.
  • However, we observed that obesity may be associated with rectosigmoid colon polyps.
  • Furthermore, age and triglyceride level might be the risk factors of colonic adenomatous polyps in Korean population.
  • [MeSH-major] Adenomatous Polyps / complications. Colonic Neoplasms / complications. Obesity / complications
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Body Mass Index. Colonic Polyps / complications. Colonic Polyps / epidemiology. Colonic Polyps / pathology. Comorbidity. Female. Humans. Korea. Male. Middle Aged. Retrospective Studies. Sigmoidoscopy

  • Genetic Alliance. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167428.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


6. Murff HJ, Shrubsole MJ, Smalley WE, Wu H, Shyr Y, Ness RM, Zheng W: The interaction of age and hormone replacement therapy on colon adenoma risk. Cancer Detect Prev; 2007;31(2):161-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The interaction of age and hormone replacement therapy on colon adenoma risk.
  • BACKGROUND: Several studies have identified a possible interaction between age and hormone replacement therapy on colon neoplasm risk.
  • RESULTS: There was a significant interaction between age and hormone replacement therapy use (P=0.03) with current estrogen users who were over 56 years of age having a reduced odds of colon adenoma (OR, 0.40; 95% CI, 0.16-0.98) when compared to never users.
  • Both older women who had used hormone replacement therapy for 3 or less years (OR, 0.07; 95% CI, 0.006-0.81) and those reporting greater than 10 years of use (OR, 0.27; 95% CI, 0.09-0.80) had a reduced adjusted odds for adenomas when compared to non-users.
  • CONCLUSIONS: Duration of use is not likely to explain the stronger association of hormone replacement therapy use with colon neoplasm in older women.

  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):443-7 [10794491.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Res. 2001 Jan 1;61(1):126-30 [11196149.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 5;93(23):1799-805 [11734596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):622-9 [12101109.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):546-52 [15066918.001]
  • [Cites] Lancet. 1970 Sep 12;2(7672):535-7 [4195202.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):359-66 [8080948.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] J Natl Cancer Inst. 1995 Jul 19;87(14):1067-71 [7616598.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):130-8 [9134236.001]
  • [Cites] Cancer Causes Control. 1997 Mar;8(2):146-58 [9134238.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):329-33 [9568789.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Aug;7(8):653-9 [9718216.001]
  • [Cites] N Engl J Med. 1999 Jan 14;340(2):101-7 [9887161.001]
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):212-7 [10211498.001]
  • [Cites] Am J Med. 1999 May;106(5):574-82 [10335731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1219-23 [15894675.001]
  • [Cites] Cancer Causes Control. 2005 Oct;16(8):965-73 [16132805.001]
  • (PMID = 17433566.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA095103; United States / NCI NIH HHS / CA / K07 CA114029; United States / NCI NIH HHS / CA / R01 CA097386-01; United States / NCI NIH HHS / CA / K07 CA114029-01A2; United States / NCI NIH HHS / CA / R01 CA097386; United States / NCI NIH HHS / CA / P50 CA095103-01; United States / NCI NIH HHS / CA / CA95103; United States / NCI NIH HHS / CA / CA097386-01; United States / NCI NIH HHS / CA / R01 CA97386
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS24075; NLM/ PMC1949417
  •  go-up   go-down


7. Kaneko R, Sato Y, An Y, Nakagawa M, Kusayanagi S, Kamisago S, Umeda T, Ogawa M, Munakata K, Mizuno K: Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma. Asian Pac J Cancer Prev; 2010;11(4):975-83
MedlinePlus Health Information. consumer health - Metabolic Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-epidemiologic study of the metabolic syndrome and lifestyle factors associated with the risk of colon adenoma and adenocarcinoma.
  • Prevention is clearly important and the present study aimed to clarify risk factors and to promote colon cancer screening.
  • RESULTS: Low-grade adenoma was more frequent among the elderly and in men.
  • All of the men and 87.5% of the women with high-grade adenoma or adenocarcinoma were aged≥45 and≥50 years, respectively.
  • In women, a larger waist circumference (=80 cm) increased the odds ratio for colon adenoma or adenocarcinoma (colon tumors) by 1.033 (95% confidence index (CI), 1.001-1.066; p=0.040).
  • Metabolic syndrome significantly increased the odds ratio of colon tumors in men, but not in women.
  • Cigarette smoking, drinking alcohol, and increased physical activity were significant risk factors for colon tumors in men, with odds ratios of 1.001 (95% CI, 1.000-1.002; p=0.001), 1.001 (95% CI, 1.000-1.003; p=0.047), and 1.406 (95% CI 1.038-1.904; p=0.028), respectively.
  • CONCLUSIONS: Colon tumors have a high prevalence in the elderly.
  • A larger waist circumference in women and metabolic syndrome in both men and women elevate the risk of colon tumors.
  • In addition, smoking, drinking, and excessive physical activity are risk factors for adenoma and adenocarcinoma in men.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenoma / epidemiology. Colorectal Neoplasms / epidemiology. Metabolic Syndrome X / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133610.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


8. Kim SE, Shim KN, Jung SA, Yoo K, Moon IH: An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol; 2007 Aug;42(8):616-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An association between obesity and the prevalence of colonic adenoma according to age and gender.
  • BACKGROUND: Epidemiologic data on obesity as a risk factor for colonic adenoma with respect to gender have not yet been confirmed.
  • Here, we aimed to compare the prevalence of colonic adenoma and of advanced polyps in age-stratified men and women at baseline, to examine the role of body mass index (BMI) on colonic adenoma risk according to age and gender, and to examine the influence of menopausal status.
  • BMI was assessed, and histology, size, and location of the adenoma were examined for each patient.
  • RESULTS: A significant increase in the prevalence of colonic adenoma and of advanced polyps was found to occur with age (P for trend < 0.01).
  • The prevalences of adenoma and advanced polyps were higher in men in most age groups (P < 0.01), but no significant difference in prevalences was observed between genderes in patients 70 years of age or older.
  • Moreover, a positive association between BMI and the prevalence of colonic adenoma and advanced polyps was shown in relatively young individuals of both gender (men in their thirties, P < 0.05; women in their forties, P < 0.05), and premenopausal women according to hormonal status (P = 0.01).
  • CONCLUSIONS: Our data suggest that obesity increases the risk of colonic adenoma in relatively young people and in premenopausal women subject to estrogen effects.
  • [MeSH-major] Adenoma / epidemiology. Colonic Neoplasms / epidemiology. Obesity / complications
  • [MeSH-minor] Adult. Age Factors. Aged. Biopsy. Body Mass Index. Colonic Polyps / epidemiology. Colonic Polyps / etiology. Colonic Polyps / pathology. Colonoscopy. Female. Humans. Korea / epidemiology. Male. Menopause. Middle Aged. Prevalence. Retrospective Studies. Risk Factors. Sex Factors

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701124.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Kuefner MA, Schwelberger HG, Hahn EG, Raithel M: Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma. Dig Dis Sci; 2008 Feb;53(2):436-42
Hazardous Substances Data Bank. HISTAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased histamine catabolism in the colonic mucosa of patients with colonic adenoma.
  • INTRODUCTION: Alterations in mucosal histamine degradation play an important role in various gastrotinestinal diseases including colonic adenoma.
  • METHODS: About 94 colonic biopsies were endoscopically obtained from 23 patients suffering from colonic adenoma and 26 biopsies from six healthy individuals.
  • RESULTS: In adenoma patients DAO activities were slightly and HNMT activities were significantly decreased in normal mucosa compared to controls.
  • Activities of both enzymes were significantly lower in adenoma tissue than in healthy mucosa in the same patients.
  • Histamine concentrations were elevated in adenoma patients.
  • CONCLUSIONS: Histamine catabolism is decreased in the colonic mucosa of patients with colonic adenoma.
  • [MeSH-major] Adenoma / metabolism. Colonic Neoplasms / metabolism. Histamine / metabolism. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma, Villous / metabolism. Adult. Aged. Amine Oxidase (Copper-Containing) / metabolism. Female. Histamine N-Methyltransferase / metabolism. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562176.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 820484N8I3 / Histamine; EC 1.4.3.21 / Amine Oxidase (Copper-Containing); EC 2.1.1.8 / Histamine N-Methyltransferase
  •  go-up   go-down


10. Pusztaszeri M, Bouzourene H: Invasive carcinoma arising from a colonic adenoma with clear cell change. Hum Pathol; 2008 Sep;39(9):1402-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive carcinoma arising from a colonic adenoma with clear cell change.
  • Clear cell change (CCC) in colonic adenoma is rare, and its biological and clinical significance remains unknown.
  • Malignant progression of an adenoma with CCC has seldom been reported.
  • We report a case of a sigmoid adenoma with multiple foci of CCC associated with high-grade dysplasia and invasive carcinoma in a 62-year-old patient.
  • We evaluated the histochemical and immunohistochemical characteristics of each component of the adenoma.
  • In contrast to other parts of the adenoma, p53 was strongly and diffusely overexpressed in the areas of CCC, high-grade dysplasia, and carcinoma.
  • The MIB-1 labeling index was also significantly higher in these components than in other parts of the adenoma.
  • In conclusion, our findings suggest that CCC in adenoma may be associated with malignant progression of the adenoma.
  • Hence, for practical purposes, we recommend considering CCC in colonic adenomas as a high-grade dysplasia equivalent and following up the patient accordingly.
  • [MeSH-major] Adenoma / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602669.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Pantanowitz L: Colonic adenoma with squamous metaplasia. Int J Surg Pathol; 2009 Aug;17(4):340-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic adenoma with squamous metaplasia.
  • Squamous metaplasia arising within colon adenomas is a rare occurrence, with a 0.4% incidence noted predominantly in elderly males.
  • A case of squamous metaplasia arising in a tubulovillous adenoma of the cecum, associated with adenocarcinoma, is described.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701516.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


12. Pucciarelli S, Enzo M, Agostini M, Pizzini S, Del Bianco P, Lonardi S, Friso M, Mescoli C, Urso E, Nitti D: Cell-free circulating DNA as a promising marker of colorectal cancer detection and progression. J Clin Oncol; 2009 May 20;27(15_suppl):11059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11059 Background: Since the pathologic stage is the most powerful prognostic factor for colorectal cancer (CRC), there is a strong need of non-invasive methods for early detection.
  • METHODS: cfDNA was extracted from plasma samples from 136 patients with primary CRC at different stages [median age 64 yrs; male/female 78/58; stages I-II, 61; stages III-IV, 75], and from 24 patients with adenomas [median age 67 yrs; male/female 17/7)] and from 55 clean-colon healthy subjects [median age 56 yrs; male/female 13/43).
  • The levels of cfDNA (ALU-115, ALU-247) of CRC patients (stages I-II and stages III-IV) were compared with those of healthy subjects and patients with adenoma.
  • RESULTS: The median concentrations of total cfDNA (ALU115) in the plasma samples from patients with stages III-IV and stages I-II CRC, adenoma and normal controls were 52,4, 11.9; 1.9, and 1.7 ng/ml, respectively (p<.0001).
  • With a cut-off of 4.86 ng/ml, total DNA (ALU115) showed a sensitivity of 78.52 (95% CI 70.6-85.1) and a specificity of 86.08 (95% CI 76.4-92.8) in distinguishing patients with CRC from non-CRC [AUC: 0.860 (95% CI 0.81-0,90), p-value=.0001].
  • With a cut-off of 3.04, cfDNA tumor-related (ALU247) showed a sensitivity of 77.94 (95% CI 70.0-84.6) and a specificity of 82.28 (95% CI 72.1-90.0) in distinguishing patients with CRC from non-CRC [AUC: 0.864 (95% CI 0.81-0,91), p-value=.0001].
  • CONCLUSIONS: Both ALU115 and ALU 247 fragments of circulating cfDNA seem promising non-invasive molecular markers of detection and progression of CRC.
  • The findings of the current study require to be confirmed on larger cohorts of patients with CRC and colonic adenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963165.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Yoshida I, Suzuki A, Vallée M, Matano Y, Masunaga T, Zenda T, Shinozaki K, Okada T: Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon. Clin Gastroenterol Hepatol; 2006 Oct;4(10):1225-31
MedlinePlus Health Information. consumer health - Diabetes Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon.
  • BACKGROUND & AIMS: Obesity and diabetes mellitus are associated with an increased incidence of proximal colon cancer.
  • Colonic adenoma that has been reported to be associated with elevated serum insulin levels and subsets of hyperplastic polyps might serve as a precursor of colon cancer.
  • In this study, we sought to determine segment-specific associations between serum insulin levels and the prevalence of adenoma and hyperplastic polyps in the proximal and distal colon.
  • We performed multinomial logistic regression models by using the outcome categories of none (reference), proximal-only, distal-only, and both-segment lesions for the presence of adenoma/hyperplastic polyp with serum insulin, age, gender, lifestyle characteristics, and the presence of other types of lesions as predictors.
  • RESULTS: Overall, serum insulin levels were significantly associated with adenoma (OR, 1.5; 95% CI, 1.1-2.0; P = .005) and borderline associated with hyperplastic polyps (OR, 1.3; 95% CI, 1.0-1.7; P = .075).
  • In multinomial logistic regression models, elevated serum insulin levels were significantly associated with proximal-only adenoma (OR, 1.8; 95% CI, 1.2-2.5; P = .002), both-side hyperplastic polyp (OR, 1.7; 95% CI, 1.1-2.5; P = .015), and proximal-only hyperplastic polyp (OR, 1.5; 95% CI, 1.0-2.1; P = .048) and borderline associated with distal-only adenoma (OR, 1.5; 95% CI, 1.0-2.1; P =.059) but not with distal-only hyperplastic polyp.
  • CONCLUSIONS: Serum insulin levels directly correlate with the presence of adenoma and hyperplastic polyps in the proximal colon and might also less strongly correlate with the presence of distal adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / blood. Biomarkers, Tumor / blood. Colonic Polyps / blood. Colonic Polyps / epidemiology. Insulin / blood

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Gastroenterol Hepatol. 2007 Jan;5(1):137
  • (PMID = 16979948.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin
  •  go-up   go-down


14. Rubio CA: Luminal histological outline and colonic adenoma phenotypes. Anticancer Res; 2007 Sep-Oct;27(5B):3555-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luminal histological outline and colonic adenoma phenotypes.
  • BACKGROUND: The luminal appearance of histological sections from colonic adenomas exhibits two different profiles: one regularly smooth and the other asymmetrically lumpy.
  • MATERIALS AND METHODS: For this purpose, the largest section of 107 consecutive endoscopically removed colonic adenomas was digitalized using an Epson Perfection 4990 PHOTO device.
  • RESULTS: Asymmetrically lumpy profiles were found in 96% (22/23) of the sections from adenomas measuring > or =15 mm, in 72% (39/54) of those having villous, mixed serrated or microtubular configurations and in 89% (24/27) showing carcinoma according to the Vienna classification.
  • CONCLUSION: The asymmetrically lumpy profile of sections from endoscopically excised colonic adenomas correlated with the size of the sections, the histological phenotype and the degree of neoplastic transformation.
  • Studies have been initiated to clinically explore whether the luminal configuration of colonic adenomas can be of help in predicting, before endoscopical removal, accepted histological parameters.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972517.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


15. Shin JE, Jung SA, Kim SE, Joo YH, Shim KN, Kim TH, Yoo K, Moon IH: [Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer]. Korean J Gastroenterol; 2007 Jul;50(1):9-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of MMP-2, HIF-1alpha and VEGF in colon adenoma and colon cancer].
  • BACKGROUND/AIMS: This study was aimed to investigate the expression of matrix metalloproteinase-2 (MMP-2), hypoxia-inducible factor (HIF)-1alpha, and vascular endothelial growth factor (VEGF) in colonic adenoma-carcinoma sequence.
  • METHODS: Thirty-two tissue samples of colon adenoma, 11 of early colon cancer and 36 of advanced colon cancer were collected by colonoscopic biopsy.
  • Normal colonic tissues were also collected from the same subjects.
  • RESULTS: The expression level of MMP-2 mRNA showed a progressive increase in the advance of the colorectal adenoma-carcinoma sequence (p<0.05).
  • In colon cancer tissues, the expression level of MMP-2 mRNA showed an increasing trend according to differentiation, lymphatic invasion and Dukes' stage (p<0.05).
  • The mRNA expression levels of HIF-1alpha and VEGF were greater in tissues of early and advanced colon cancer compared with colon adenoma (p<0.05; p<0.001).
  • CONCLUSIONS: MMP-2, HIF-1alpha, and VEGF may be useful in detecting early carcinogenesis and progression of colon cancer.
  • [MeSH-major] Adenoma / metabolism. Colonic Neoplasms / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Matrix Metalloproteinase 2 / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18172354.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


16. Harada K, Higaki S, Amano A, Hashimoto K, Hashimoto S, Gondo T, Sakaida I: A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon. Oncol Rep; 2007 Jun;17(6):1353-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A reduced COX-2 expression and a reduced number of pericryptal myofibroblasts are associated with depressed adenoma of the colon.
  • The histogenesis of depressed adenoma of the colon has not been sufficiently investigated.
  • Pericryptal myofibroblasts are stromal cells expressing smooth muscle actin, and are involved in the differentiation and multiplication of epithelial cells in the colonic epithelium.
  • COX-2 has been reported to be involved in the development of colon adenoma.
  • We studied the histogenesis of depressed adenoma of the colon by examining the relationship between the presence of pericryptal myofibroblasts and COX-2 expression.
  • Twenty-one depressed adenomas of the colon that had been resected endoscopically between June 1998 and May 2003 (mild-moderate atypia; mean diameter, 6.7 mm) and 23 elevated adenomas that had been resected endoscopically in 2003 (mild-moderate atypia; mean diameter, 11.7 mm), were studied.
  • Eighteen (78.3%) of the 23 elevated adenomas and six (28.6%) of the 21 depressed adenomas were positive for pericryptal myofibroblasts immunohistochemically, showing a significant difference (P<0.001).
  • Seventeen elevated adenomas (73.9%) and eight depressed adenomas (38.1%) were positive for COX-2 expression (P=0.016).
  • The histogenesis of depressed adenomas differs from that of elevated adenomas.
  • Our results suggest that a low number of pericryptal myofibroblasts and a low COX-2 expression are associated with depressed adenomas.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Cyclooxygenase 2 / metabolism. Fibroblasts / pathology. Membrane Proteins / metabolism. Myoblasts / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487390.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Actins; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


17. Tanaka S, Tatsuguchi A, Futagami S, Gudis K, Wada K, Seo T, Mitsui K, Yonezawa M, Nagata K, Fujimori S, Tsukui T, Kishida T, Sakamoto C: Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut; 2006 Jan;55(1):54-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma.
  • BACKGROUND AND AIMS: Cyclooxygenase 2 (COX-2) expression in subepithelial macrophages of colorectal adenoma has been suggested as the first in a series of steps leading to colorectal tumorigenesis.
  • We tested the hypothesis that chemokines released from human colorectal adenoma epithelium might be involved in COX-2 expression in macrophages of the lamina propria.
  • METHODS: Endoscopic samples of sporadic colorectal adenomas were tested by enzyme linked immunosorbent assay for chemokines involved in macrophage chemotaxis.
  • Localisation of adenoma macrophage chemoattractant protein 1 (MCP-1) and COX-2 were determined by immunohistochemistry.
  • RESULTS: MCP-1 levels were markedly higher in adenoma with mild-moderate dysplasia (129.7 (19.9) pg/mg protein) and severe dysplasia (227.9 (35.4) pg/mg protein) than in normal colonic mucosa (55.8 (4.2) pg/mg protein).
  • Other chemokine levels, macrophage inflammatory proteins (MIP)-1alpha and MIP-1beta, and the chemokine regulated on activation of normal T cell expressed and secreted (RANTES) did not vary significantly between adenoma and normal mucosa.
  • MCP-1 levels in both adenoma and normal colonic mucosa increased significantly three hours after tissue cultivation in vitro.
  • MCP-1 immunoreactivity was restricted to the adenoma epithelium, with no reactivity seen in adjacent normal epithelial cells.
  • Addition of exogenous PGE(2) reversed this inhibitory effect on VEGF release, suggesting that MCP-1 in adenoma epithelial cells might be involved in COX-2 expression and subsequent macrophage activation.
  • CONCLUSIONS: MCP-1 in colorectal adenoma epithelial cells might be involved in macrophage migration and COX-2 expression, leading to the subsequent development of colonic adenoma.
  • [MeSH-major] Adenoma / metabolism. Chemokine CCL2 / metabolism. Colorectal Neoplasms / metabolism. Cyclooxygenase 2 / metabolism. Macrophages / enzymology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CELECOXIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):751-8 [10544003.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):470-5 [10508481.001]
  • [Cites] J Pharmacol Exp Ther. 2000 May;293(2):539-44 [10773026.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Jun;19(2):219-23 [10965822.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Nov;295(2):802-9 [11046121.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6045-51 [11085526.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1733-40 [11245490.001]
  • [Cites] Acta Oncol. 2001;40(5):622-8 [11669335.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1339-47 [11729113.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1669-75 [11912138.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):220-4 [12397639.001]
  • [Cites] J Pathol. 2002 Dec;198(4):435-41 [12434412.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2736-41 [12598658.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):883-90 [12621132.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):773-8 [12632067.001]
  • [Cites] Gastroenterology. 2003 Aug;125(2):328-36 [12891533.001]
  • [Cites] Cancer Causes Control. 2003 Jun;14(5):403-11 [12946034.001]
  • [Cites] Gut. 2003 Oct;52(10):1448-56 [12970138.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1317-22 [14532971.001]
  • [Cites] Ann Intern Med. 2004 Feb 3;140(3):157-66 [14757613.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):488-95 [15116331.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Aug;287(2):G444-51 [15246970.001]
  • [Cites] J Surg Oncol. 1983 Sep;24(1):83-7 [6887943.001]
  • [Cites] Am J Surg. 1989 Jan;157(1):175-9 [2535920.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4482-6 [7753829.001]
  • [Cites] N Engl J Med. 1995 Sep 7;333(10):609-14 [7637720.001]
  • [Cites] J Immunol. 1995 Dec 15;155(12):5769-76 [7499865.001]
  • [Cites] Eur J Immunol. 1995 Dec;25(12):3482-8 [8566041.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4625-9 [8840975.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] Gastroenterology. 1997 Feb;112(2):387-97 [9024292.001]
  • [Cites] Arch Intern Med. 1999 Jan 25;159(2):161-6 [9927099.001]
  • [Cites] Acta Obstet Gynecol Scand. 1999 Mar;78(3):240-4 [10078587.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1399-405 [10188882.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1107-13 [10353745.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):545-53 [10666384.001]
  • (PMID = 16085694.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Chemokine CCL2; 0 / Chemokines; 0 / Cyclooxygenase Inhibitors; 0 / Neoplasm Proteins; 0 / Pyrazoles; 0 / Sulfonamides; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC1856393
  •  go-up   go-down


18. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET: Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res; 2010 Feb 15;70(4):1496-504
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.
  • No gene-level associations were observed for VDR, nor was any single SNP in VDR related to any metachronous adenoma after correction for multiple comparisons.
  • Haplotypes within linkage blocks of RXRA support an approximately 30% reduction in odds of metachronous neoplasia arising in the proximal colon among carriers of specific haplotypes, which was strongest (OR(proximal), 0.67; 95% CI, 0.52-0.86) for carriers of a CGGGCA haplotype (rs1805352, rs3132297, rs3132296, rs3118529, rs3118536, and rs7861779).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2006 Nov;27(11):1129-34 [16937379.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1706-16 [17087956.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] J Clin Gastroenterol. 2007 Sep;41(8):731-46 [17700421.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Gut. 2007 Nov;56(11):1557-63 [17604322.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] PLoS One. 2008;3(1):e1483 [18213391.001]
  • [Cites] Nutr Cancer. 2008;60(1):97-108 [18444141.001]
  • [Cites] Cell Mol Life Sci. 2008 May;65(10):1523-43 [18278436.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):586-93 [18470879.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):944-8 [18375961.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S98-112 [18844852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2958-69 [18990737.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):769-76 [19255064.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1170-80 [19403841.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):3931-9 [11089522.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):369-87 [11470825.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):869-74 [11489753.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):607-14 [11552708.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25313-22 [12000762.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):488-94 [12829024.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29954-62 [12771132.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7799-806 [14633706.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8 [15342452.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Endocrinology. 1994 Apr;134(4):1710-7 [8137734.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):623-32 [8564982.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S57-73 [9379138.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • [Cites] Hum Genet. 1998 Oct;103(4):462-9 [9856491.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):144-51 [16004730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2061-3 [16172209.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):898-915 [16126938.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):629-44 [16532393.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Anticancer Res. 2009 Sep;29(9):3511-36 [19667145.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1030-4 [16936639.001]
  • (PMID = 20145122.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106269; United States / NCI NIH HHS / CA / CA023074-22S1; United States / NCI NIH HHS / CA / P50 CA095060-01; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / K07CA106269; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / CA77145; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA095060-01; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / R01 CA123065; United States / NCI NIH HHS / CA / K07 CA106269-01A1; United States / NCI NIH HHS / CA / P30 CA023074-22S1; United States / NCI NIH HHS / CA / P01 CA041108-13; United States / NCI NIH HHS / CA / P01CA41108; United States / NCI NIH HHS / CA / CA041108-13; United States / NCI NIH HHS / CA / CA106269-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Retinoid X Receptor alpha
  • [Other-IDs] NLM/ NIHMS262521; NLM/ PMC3019606
  •  go-up   go-down


19. Veeriah S, Hofmann T, Glei M, Dietrich H, Will F, Schreier P, Knaup B, Pool-Zobel BL: Apple polyphenols and products formed in the gut differently inhibit survival of human cell lines derived from colon adenoma (LT97) and carcinoma (HT29). J Agric Food Chem; 2007 Apr 18;55(8):2892-900

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apple polyphenols and products formed in the gut differently inhibit survival of human cell lines derived from colon adenoma (LT97) and carcinoma (HT29).
  • Here, apple polyphenols were studied for effects on the survival of colon adenoma (LT97) and carcinoma-derived (HT29) cell lines.
  • [MeSH-major] Cell Survival / drug effects. Colonic Neoplasms / pathology. Fermentation. Flavonoids / pharmacology. Fruit / chemistry. Malus / chemistry. Phenols / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17378580.001).
  • [ISSN] 0021-8561
  • [Journal-full-title] Journal of agricultural and food chemistry
  • [ISO-abbreviation] J. Agric. Food Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Phenols; 0 / Plant Extracts; 0 / Polyphenols
  •  go-up   go-down


20. Wei HJ, Guo ZY, Xie SS, He BH, Li LB, Chen XM, Wu GY, Lu JJ: [Colon adenoma detection using Kubelka-Munk spectral function of DNA and protein bands]. Guang Pu Xue Yu Guang Pu Fen Xi; 2009 Jun;29(6):1473-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colon adenoma detection using Kubelka-Munk spectral function of DNA and protein bands].
  • Differential diagnosis of human colon adenoma was studied using the Kubelka-Munk spectral function of the DNA and protein absorption bands at 260 and 280 nm in vitro.
  • The results of measurement showed that for the spectral range from 590 to 1 064 nm pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the DNA absorption bands at 260 nm between normal and adenomatous colon epithelial tissues, and the differences were 218% (p < 0.05) and 68.5% (p < 0.05) respectively.
  • Pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the protein absorption bands at 280 nm between normal and adenomatous colon epithelial tissues, and the differences were 208% (p < 0.05) and 59.0% (p < 0.05) respectively.
  • Pathological changes of colon epithelial tissues were induced so that there were significant differences in the averaged values of the Kubelka-Munk function f(r infinity) and logarithmic Kubelka-Munk function log [f(r infinity)] of the beta-carotene absorption bands at 480 nm between normal and adenomatous colon epithelial tissues, and the differences were 41.7% (p < 0.05) and 32.9% (p < 0.05) respectively.
  • Obviously, pathological changes of colon epithelial tissues were induced so that there were significant changes in the contents of the DNA, protein and beta-carotene of colon epithelial tissues.
  • The conclusion can be applied to rapid, low-cost and noninvasive optical biopsy of colon adenoma, and provides a useful reference.
  • [MeSH-major] Adenoma / diagnosis. Colonic Neoplasms / diagnosis. DNA / chemistry. Proteins / chemistry. Spectrum Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810511.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proteins; 9007-49-2 / DNA
  •  go-up   go-down


26. Friedland S, Soetikno R, Carlisle M, Taur A, Kaltenbach T, Segall G: 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc; 2005 Mar;61(3):395-400
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18-Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer.
  • BACKGROUND: 18-Fluorodeoxyglucose positron emission tomography (PET) is used clinically to detect recurrent colon cancer after surgical resection, but the sensitivity of PET for premalignant colon lesions and early stage colon cancer is not well defined.
  • METHODS: In a prospective study, 45 patients with a total of 58 colonic neoplasms, including premalignant polyps, premalignant, flat lesions, and early stage cancers, were evaluated by PET.
  • CONCLUSIONS: PET has limited sensitivity for flat, premalignant lesions; protruded, premalignant lesions smaller than 3 cm; and colon cancers smaller than 2 cm.
  • [MeSH-major] Adenoma / diagnostic imaging. Colonic Neoplasms / diagnostic imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography. Precancerous Conditions / diagnostic imaging. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15758910.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


27. Schindler AE: Long-term use of progestogens: colon adenoma and colon carcinoma. Gynecol Endocrinol; 2007 Oct;23 Suppl 1:42-4
MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term use of progestogens: colon adenoma and colon carcinoma.
  • Colon cancer is the second most common cancer in women in the Western world and there is a trend towards an increasing risk.
  • Colon adenoma is a potential precursor for colon cancer.
  • Adenoma and carcinoma of the colon seem to be influenced by estrogens and progesterone/progestins.
  • This is related to the presence of estrogen and progesterone receptors, with apparently higher concentrations in colon cancers than in adenomas.
  • Epidemiological data and the finding of a significant reduction in colon cancer risk related to hormone replacement therapy (HRT), and in particular the length of HRT intake, indicate that progesterone/progestins have a preventive effect.
  • Furthermore, the recurrence rate of adenoma appears to be reduced, and the survival of colon cancer patients improved, with HRT; such effects have not been documented with ERT.
  • [MeSH-major] Adenoma / prevention & control. Carcinoma / prevention & control. Colonic Neoplasms / prevention & control. Hormone Replacement Therapy. Progestins / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943538.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins
  • [Number-of-references] 22
  •  go-up   go-down


28. Giardiello FM, Hylind LM, Trimbath JD, Hamilton SR, Romans KE, Cruz-Correa M, Corretti MC, Offerhaus GJ, Yang VW: Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology; 2005 Apr;128(4):1077-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral contraceptives and polyp regression in familial adenomatous polyposis.
  • We describe a patient in the placebo arm of a 4-year primary chemoprevention trial who developed adenomatous polyps and then had eradication of polyps after the administration of oral contraceptives.
  • No change in the prostaglandin levels in the colonic mucosa was noted after polyp elimination, making nonsteroidal anti-inflammatory drug ingestion unlikely as a cause.
  • This report represents the regression of colorectal adenomas with the use of estrogen/progesterone compounds.
  • [MeSH-major] Adenomatous Polyposis Coli / physiopathology. Contraceptives, Oral / therapeutic use
  • [MeSH-minor] Child. Colon / metabolism. Female. Humans. Intestinal Mucosa / metabolism. Menstruation Disturbances / drug therapy. Prostaglandins / metabolism. Remission Induction

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15825088.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 51085; United States / NCI NIH HHS / CA / CA 53801; United States / NCI NIH HHS / CA / CA 63721; United States / NCI NIH HHS / CA / P50 CA 9316
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral; 0 / Prostaglandins
  •  go-up   go-down


29. Hazra A, Fuchs CS, Chan AT, Giovannucci EL, Hunter DJ: Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk. Cancer Causes Control; 2008 Nov;19(9):975-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of the TCF7L2 polymorphism with colorectal cancer and adenoma risk.
  • We evaluated the association of a polymorphism in TCF7L2 (RS12255372) in the WNT signaling pathway, which previously has been strongly associated with risk of Type II Diabetes, with colorectal cancer (CRC) and adenoma in the prospective Nurses' Health Study (NHS) and Health Professionals Follow-up Study (HPFS) cohorts.
  • Hyperinsulinemia may be related to the risk of colon adenoma and cancer, therefore this variant associated with reduced insulin secretion would be predicted to be inversely associated with colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2006 Jul 27;25(32):4441-8 [16547505.001]
  • [Cites] N Engl J Med. 2006 Jul 20;355(3):241-50 [16855264.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2645-8 [16936216.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2649-53 [16936217.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2654-9 [16936218.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2890-5 [17003358.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] BMC Cancer. 2006;6:268 [17109766.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2408-17 [17164363.001]
  • [Cites] Diabetologia. 2007 Jan;50(1):5-7 [17102948.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3872-9 [10919662.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Curr Biol. 1998 May 7;8(10):573-81 [9601641.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Genet Anal. 1999 Feb;14(5-6):143-9 [10084106.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4213-5 [10485457.001]
  • [Cites] Cancer Causes Control. 1999 Oct;10(5):379-86 [10530607.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1457-64 [15525634.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):850-5 [15824155.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):863-70 [15824157.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):320-3 [16415884.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1830-7 [16410309.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):750-5 [16614119.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2640-4 [16936215.001]
  • (PMID = 18478343.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA87969; United States / NCI NIH HHS / CA / T-32 CA 09001-30; United States / NCI NIH HHS / CA / K07 CA107412; United States / NCI NIH HHS / CA / CA70817; United States / NCI NIH HHS / CA / CA55075; United States / NCI NIH HHS / CA / CA107412-03; United States / NCI NIH HHS / CA / K07 CA107412-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Transcription Factor 7-Like 2 Protein
  • [Other-IDs] NLM/ NIHMS124556; NLM/ PMC2719293
  •  go-up   go-down


30. Fujiya M, Moriichi K, Saitoh Y, Watari J, Kohgo Y: Endoscopic piecemeal resection is a practical option to cure colorectal tumors. Dig Endosc; 2009 Jul;21 Suppl 1:S28-30
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endoscopic mucosal resection (EMR) and endoscopic piecemeal resection (EPMR) are therapeutic options widely accepted for the treatment of colon adenoma, intramucosal cancer and minimally invasive submucosal cancer.
  • [MeSH-major] Adenoma / surgery. Colonoscopy / methods. Colorectal Neoplasms / surgery. Intestinal Mucosa / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691729.001).
  • [ISSN] 1443-1661
  • [Journal-full-title] Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
  • [ISO-abbreviation] Dig Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


31. Ramirez M, Schierling S, Papaconstantinou HT, Thomas JS: Management of the malignant polyp. Clin Colon Rectal Surg; 2008 Nov;21(4):286-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the malignant polyp.
  • In the United States, the prevalence of adenomatous polyps found during colonoscopic evaluation ranges from 25 to 41%, and of these, 2 to 5% contain invasive malignancy.
  • The management of the malignant polyp continues to be challenging.
  • Endoscopic resection by polypectomy has been shown to be sufficient for management of certain polyps containing cancer; however, it is important to keep in mind that polypectomy does not remove the lymph node drainage basin and may be an inadequate resection for some adenocarcinoma containing polyps that have specific histologic features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 1999 Mar;13(3):231-2 [10064752.001]
  • [Cites] Gastroenterology. 1990 Feb;98(2):371-9 [2403953.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] World J Surg. 2000 Sep;24(9):1047-51 [11036280.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Ann Surg. 1975 Oct;182(4):516-25 [1180588.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):200-6 [11852333.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Surg Clin North Am. 2002 Oct;82(5):959-66 [12507202.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):177-81 [12892794.001]
  • [Cites] Dis Colon Rectum. 2005 Aug;48(8):1588-96 [15937622.001]
  • [Cites] Gastroenterology. 1991 Jan;100(1):64-7 [1796931.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):941-5 [1858757.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):946-51 [1858758.001]
  • [Cites] World J Surg. 1991 Jan-Feb;15(1):35-40 [1994604.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1937-47 [2477139.001]
  • [Cites] Gastroenterology. 1986 Aug;91(2):419-27 [3721127.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1657-65 [7768369.001]
  • [Cites] Am J Gastroenterol. 1994 Oct;89(10):1775-80 [7942665.001]
  • [Cites] Endoscopy. 1993 Sep;25(7):455-61 [8261988.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Gastroenterology. 1985 Aug;89(2):328-36 [4007423.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):67-72 [12832967.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] Zentralbl Chir. 2004 Aug;129(4):291-5 [15354251.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1789-96; discussion 1796-7 [15622570.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Jan;22(1):54-9 [16319677.001]
  • [Cites] CA Cancer J Clin. 1997 Mar-Apr;47(2):93-112 [9074488.001]
  • [Cites] Cancer. 1992 Sep 1;70(5 Suppl):1236-45 [1511370.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • (PMID = 20011440.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780260
  • [Keywords] NOTNLM ; Haggitt level / Malignant polyp / adenocarcinoma / adenomatous polyp / endoscopic polypectomy / segmental colectomy
  •  go-up   go-down


32. Lim YJ, Kwack WG, Lee YS, Hahm KB, Kim YK: Increased pulse wave velocity reflecting arterial stiffness in patients with colorectal adenomas. J Clin Biochem Nutr; 2010 Nov;47(3):261-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased pulse wave velocity reflecting arterial stiffness in patients with colorectal adenomas.
  • The obese patients with diabetes or cardiovascular risk factors are associated with increased risk of colorectal cancer as well as adenomas under the shared pathogenesis related to atherosclerosis.
  • Here we determined the association between increased arterial stiffness and colorectal adenomas incorporating parameters including age, gender, waist circumference, body mass index, lipid profiles, fasting glucose, and blood pressure.
  • Subjects who simultaneously underwent colonoscopies and pulse wave velocity (PWV) determinations between July 2005 and September 2006 were analyzed, based on which the subjects were classified into two groups as patients group with colorectal adenomas (n = 49) and control group (n = 200) with normal, non-polypoid benign lesions or hyperplastic polyps.
  • Uni- and multi-variate analyses were performed to calculate the odd ratio for colon adenomas.
  • Based on uni-variate analysis, age, waist circumference, body mass index, heart-femoral PWV (hfPWV), and brachial-ankle PWV were significantly associated with adenomas (p<0.05) and multiple logistic regression analysis showed that the heart-femoral PWV, waist circumference, and the levels of LDL-C were significant risk factor for colorectal adenoma.
  • However, arterial stiffness did not affect the progression of colon adenoma.
  • The finding that hfPWV, reflecting aortic stiffness, was increased in patients with colorectal adenomas lead to conclusion that patients who have prominently increased arterial stiffness can be recommended to undergo colonoscopic examinations and at the same time we also recommend counseling about the risk for atherosclerosis in those who have colorectal adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103036.001).
  • [ISSN] 1880-5086
  • [Journal-full-title] Journal of clinical biochemistry and nutrition
  • [ISO-abbreviation] J Clin Biochem Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2966937
  • [Keywords] NOTNLM ; atherosclerosis / colon adenoma / pulse wave velocity / risk factors
  •  go-up   go-down


33. Wu K, Giovannucci E, Byrne C, Platz EA, Fuchs C, Willett WC, Sinha R: Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men. Cancer Epidemiol Biomarkers Prev; 2006 Jun;15(6):1120-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meat mutagens and risk of distal colon adenoma in a cohort of U.S. men.
  • We examined the association between intakes of the heterocyclic amines 2-amino-3,8-dimethylimidazo[4,5,-f]quinoxaline (MeIQx), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), 2-amino-3,4,8-trimethylimidazo[4,5,-f]quinoxaline (DiMeIQx), and meat-derived mutagenicity (MDM) and risk of distal colon adenoma using a cooking method questionnaire administered in 1996 in the Health Professionals Follow-up Study cohort.
  • Between 1996 and 2002, 581 distal colon adenoma cases were identified.
  • Higher intake of MDM was marginally associated with increased risk of distal adenoma [fourth versus lowest quintile: odds ratio (OR), 1.39; 95% confidence interval (95% CI), 1.05-1.84; highest versus lowest quintile: OR, 1.29; 95% CI, 0.97-1.72; P(trend) = 0.08].
  • Our data also suggested a positive association between higher MeIQx (highest versus lowest quintile: OR, 1.28; 95% CI, 0.95-1.71; P(trend) = 0.22) and risk of adenoma, but this association was attenuated after adjusting for processed meat intake.
  • DiMeIQx and PhIP did not seem to be associated with risk of adenoma.
  • In conclusion, higher consumption of mutagens from meats cooked at higher temperature and longer duration may be associated with higher risk of distal colon adenoma independent of overall meat intake.
  • Because mutagens other than heterocyclic amines also contribute to MDM, our results suggest that mutagens other than heterocyclic amines in cooked meats may also play a role in increasing the risk of distal adenoma.
  • [MeSH-major] Adenoma / etiology. Colonic Neoplasms / etiology. Meat. Mutagens / adverse effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16775169.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 55075; United States / NCI NIH HHS / CA / CA95589
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amines; 0 / Mutagens
  •  go-up   go-down


34. Voloyiannis T, Snyder MJ, Bailey RR, Pidala M: Management of the difficult colon polyp referred for resection: resect or rescope? Dis Colon Rectum; 2008 Mar;51(3):292-5
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the difficult colon polyp referred for resection: resect or rescope?
  • PURPOSE: Patients are frequently referred for resection of difficult colon polyps.
  • Before colectomy the experienced surgeon has the option of repeating the colonoscopy to assess the polyp, tattoo the site, and potentially remove the polyp.
  • METHODS: All new patients referred during a five-year period to an 11-physician colon and rectal surgical group with the diagnosis of colon polyp (CPT 211.3) that was not previously removed were retrospectively reviewed.
  • Patients with rectal polyps, inflammatory bowel disease, previous cancer, or familial adenomatous polyposis were excluded.
  • Patient demographics, details of the polyps, success of polypectomy, reasons for surgical resection, pathology, and complications were analyzed.
  • The remaining 71 patients had a subsequent colon resection after at least one repeat colonoscopy.
  • In 26 cases the polyp site was tattooed for later localization.
  • Patients with large difficult polyps referred for resection should be considered for repeat colonoscopy before surgery.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy / utilization

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dis Colon Rectum. 2008 Aug;51(8):1300
  • (PMID = 18202891.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Erdem L, Akbayir N, Yildirim S, Köksal HM, Yenice N, Gültekin OS, Sakiz D, Peker O: Predictive value of morphologic characteristics in rectosigmoid adenomatous polyps for the probability of synchronous polyps or cancer in the proximal colon. Turk J Gastroenterol; 2005 Dec;16(4):207-11
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of morphologic characteristics in rectosigmoid adenomatous polyps for the probability of synchronous polyps or cancer in the proximal colon.
  • The necessity of colonoscopy in patients with an adenoma of<or=5 mm found on sigmoidoscopy is controversial.
  • The aim of this study was to investigate whether the size of rectosigmoid adenomas is associated with the risk of neoplasm in the proximal colon and to determine whether there is indication for total colonoscopy.
  • METHODS: Patients found to have rectosigmoid adenomatous polyps on colonoscopy were included in the study.
  • These adenomas were grouped as diminutive (<or=5 mm), small (6-10 mm) or large (>or=11 mm) polyps.
  • These groups were compared regarding the presence of proximal adenoma and advanced proximal neoplasia (>10 mm adenoma and/or villous histology and/or high grade dysplasia or cancer).
  • Polyps found in the rectum and sigmoid colon were considered as distal polyps and polyps other than these were considered as proximal polyps.
  • RESULTS: In this study, of 1124 consecutive patients who underwent colonoscopy between April 1997 and January 2002, 184 (16%) had 258 adenomatous polyps in the rectosigmoid area.
  • The polyps were diminutive (<or=5 mm) in 105, small (6-10 mm) in 46 and large (>or=11 mm) in 33 patients.
  • Forty-one of the patients (39%) with diminutive polyps, 20 of the patients (43%) with small polyps and 19 of the patients (57%) with large polyps had neoplasm in the proximal bowel.
  • There was no difference regarding the presence of neoplasm in the proximal colon between these groups.
  • The rate of advanced proximal neoplasm was found to be significantly higher in the group with large polyps in the rectosigmoid area than in the groups with small and diminutive polyps (p<0.05).
  • In 104 patients (57%) with polyp(s) in rectum and sigmoid colon, no associated polyp or cancer was encountered in the proximal colon.
  • CONCLUSION: Colonoscopy is indicated when adenomatous polyp, regardless of size, is found on rectosigmoidoscopy performed because of symptoms.
  • [MeSH-major] Adenomatous Polyps / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasms, Multiple Primary. Rectal Neoplasms / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16547849.001).
  • [ISSN] 1300-4948
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Turkey
  •  go-up   go-down


36. Zhou PH, Yao LQ, Chen WF: [Endoscopic therapy of adenomatous polyps and early-stage carcinomas of the colon and rectum]. Zhonghua Wai Ke Za Zhi; 2008 Sep 15;46(18):1386-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic therapy of adenomatous polyps and early-stage carcinomas of the colon and rectum].
  • OBJECTIVE: To assess the clinical efficacy of endoscopic treatment for colorectal adenomatous polyps and early-stage carcinomas.
  • METHODS: Between January 2006 and October 2007, 245 patients with colorectal adenomatous polyps and early-stage carcinomas with lifting sign(+) were treated by such endoscopic techniques as polypectomy, endoscopic mucosal resection (EMR), endoscopic piecemeal mucosal resection (EPMR) and endoscopic submucosal dissection (ESD).
  • CONCLUSIONS: Endoscopic resection appears to be an efficacious procedure to treat adenomatous polyp and early-stage carcinoma and provide pathological information about the whole lesion.
  • [MeSH-major] Adenomatous Polyps / surgery. Colorectal Neoplasms / surgery. Endoscopes, Gastrointestinal

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094508.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Raumforderungen im kleinen Becken aus Sicht des Urologen.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • This is also the case with malignant tumors of the uterus, ovaries, cervix and colon where infiltration of the urogenital organs might be noted.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


38. Neneman B, Gasiorowska A, Małecka-Panas E: The efficacy and safety of argon plasma coagulation (APC) in the management of polyp remnants in stomach and colon. Adv Med Sci; 2006;51:88-93
Hazardous Substances Data Bank. Argon, Elemental .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy and safety of argon plasma coagulation (APC) in the management of polyp remnants in stomach and colon.
  • PURPOSE: Endoscopic treatment of sessile and semipedunculated polyps remains controversial.
  • The aim of the study was to assess the outcome and safety of argon plasma coagulation (APC) in the management of gastric and colorectal polyp remnants after polypectomy, and to search for clinical parameters useful in predicting the efficacy of this technique.
  • MATERIAL AND METHODS: This prospective study comprised 18 patients with gastric polyps and 29 with colonic polyps found in upper and lower GI endoscopy.
  • Overall 22 gastric polyps and 58 colonic polyps have been detected.
  • All those polyps were removed at colonoscopy with the diathermic snare and the polyp remnants were destroyed with APC using Argon Beamer source (Erbe, Germany).
  • RESULTS: Pathologic examination revealed 10 hyperplastic polyps and 12 tubular adenomas of the stomach.
  • Effective destruction of polyp remnants was achieved in 20 (90.9%) gastric polyps in 16 (88.9%) patients.
  • Significant positive correlation was demonstrated between the power output, APC sessions number and polyp location in the prepyloric part, its size and adenomatous content.
  • Among colonic polyps there were: 17 hyperplastic, 26 tubular, 8 tubulo-villous, 4 villous adenomas and 3 inflammatory pseudopolyps.
  • Effective destruction of remnant polyp tissue was obtained in 56 (96.4%) polyps in 27 (93.1%) patients.
  • A significant positive correlation between the power output and the size, distal location and villous texture of the polyp has been demonstrated.
  • CONCLUSIONS: APC is an effective and safe method in the management of polyp remnants in the stomach and colon.
  • The application of higher electric power and numerous APC sessions are necessary to remove residues of large gastric polyps located in the prepyloric part and of with adenomatous content.
  • In the case of colonic polyps the application of higher electric power should be recommended in case of large-sized lesions, located in rectum and of villous texture.
  • [MeSH-major] Colonic Polyps / surgery. Electrocoagulation / methods. Neoplasm, Residual / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adult. Aged. Argon / therapeutic use. Colonoscopy. Endoscopy. Female. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357283.001).
  • [ISSN] 1896-1126
  • [Journal-full-title] Advances in medical sciences
  • [ISO-abbreviation] Adv Med Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 67XQY1V3KH / Argon
  •  go-up   go-down


39. Hsu HH, Cheng SF, Chen LM, Liu JY, Chu CH, Weng YJ, Li ZY, Lin CS, Lee SD, Kuo WW, Huang CY: Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells. Mol Cell Biochem; 2006 Sep;289(1-2):101-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expressed estrogen receptor-alpha up-regulates hTNF-alpha gene expression and down-regulates beta-catenin signaling activity to induce the apoptosis and inhibit proliferation of LoVo colon cancer cells.
  • Epidemiologic studies reported that the prevalence of hereditary non-polyposis colon cancer (HNPCC) in male is about 1.5-fold higher than that in female.
  • Patients that received E(2) replacement therapy were found to have a reduction in the incidence of colon adenoma and carcinoma.
  • [MeSH-major] Apoptosis. Colonic Neoplasms / pathology. Estrogen Receptor alpha / metabolism. Gene Expression Regulation. Signal Transduction. Tumor Necrosis Factor-alpha / genetics. beta Catenin / metabolism
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / metabolism. Caspases / metabolism. Cell Cycle Proteins / metabolism. Cell Line, Tumor. Cell Proliferation. DNA Fragmentation. Down-Regulation / genetics. Estrogens / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic / drug effects. Transfection. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism. Up-Regulation / genetics. Wnt Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628468.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cell Cycle Proteins; 0 / Estrogen Receptor alpha; 0 / Estrogens; 0 / TNF protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; 0 / Wnt Proteins; 0 / beta Catenin; EC 3.4.22.- / Caspases
  •  go-up   go-down


40. Marino M, Galluzzo P, Leone S, Acconcia F, Ascenzi P: Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells. Endocr Relat Cancer; 2006 Jun;13(2):559-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nitric oxide impairs the 17beta-estradiol-induced apoptosis in human colon adenocarcinoma cells.
  • By contrast, E2 reduces the incidence of colon adenoma and carcinoma by about 30%.
  • We report the genomic and non-genomic E2-estrogen receptor (ER) beta-induced effects in human colon adenocarcinoma.
  • The E2-ERbeta-dependent gene transcription was inhibited by exogenous NO, whereas some non-genomic E2-dependent effects (e.g. p38/MAP kinase), important for the activation of the apoptotic cascade, were unaffected by NO.
  • However, NO impaired the E2-induced pro-apoptotic cascade in human colon adenocarcinoma cells by inhibiting caspase-3.
  • On the whole, high NO concentrations suppressed the E2 protective effects in the gastrointestinal tract, suggesting that the caspase-dependent apoptotic cascade may become critical under conditions of high redox stress such as occur under specific activation of the immune system by chronic infections or pathogen challenge.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis / drug effects. Caspase Inhibitors. Colonic Neoplasms / metabolism. Estrogen Receptor beta / antagonists & inhibitors. Nitric Oxide / toxicity

  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. CYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16728582.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Caspase Inhibitors; 0 / Estrogen Receptor beta; 31C4KY9ESH / Nitric Oxide; 4TI98Z838E / Estradiol; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; K848JZ4886 / Cysteine
  •  go-up   go-down


41. Rastogi A, Pondugula K, Bansal A, Wani S, Keighley J, Sugar J, Callahan P, Sharma P: Recognition of surface mucosal and vascular patterns of colon polyps by using narrow-band imaging: interobserver and intraobserver agreement and prediction of polyp histology. Gastrointest Endosc; 2009 Mar;69(3 Pt 2):716-22
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recognition of surface mucosal and vascular patterns of colon polyps by using narrow-band imaging: interobserver and intraobserver agreement and prediction of polyp histology.
  • BACKGROUND: The 2 main types of colon polyps are adenomas and hyperplastic.
  • Pit patterns on the surface of polyps have been described by using magnification chromoendoscopy, which can help differentiate between polyp types.
  • Narrow band imaging (NBI) is a novel technology that enhances the visualization of surface mucosal and vascular patterns on the polyp surface.
  • Earlier we described, in a pilot study, patterns seen on the polyp surface with NBI that can help differentiate between adenomas and hyperplastic polyps with a high degree of accuracy.
  • OBJECTIVE: The aim of this study was to evaluate the interobserver and intraobserver agreement (among endoscopists) for the NBI surface mucosal and vascular patterns and prediction of polyp histology and the accuracy of the investigators to predict polyp histology based on these patterns.
  • METHODS: NBI images of the polyp surface mucosal and vascular patterns obtained in our pilot trial were retrieved.
  • A teaching set of 20 images was selected to educate and demonstrate the polyp patterns to 4 endoscopists.
  • Subsequently, the test set of images was evaluated by the 4 endoscopists for quality, polyp pattern, and prediction of polyp type.
  • Interobserver agreement (k value) was calculated among the 4 assessors for the polyp patterns and predicted histology.
  • By using the final histology as the criterion standard, the accuracy of polyp-type prediction was calculated for each assessor.
  • After a period of 2 months, all polyp images were reevaluated by the assessors (as before), and all findings were recorded in a similar fashion.
  • These results were used for calculation of intraobserver agreement (k value) and the accuracy of the assessors in predicting polyp type.
  • RESULTS: Photographs of 65 polyps were included in the test set and were evaluated by the 4 assessors.
  • Thirty-eight polyps were adenomatous, and 27 were hyperplastic.
  • The kappa value for the interobserver agreement for polyp surface pattern was 0.57 (moderate) and for prediction of polyp type was 0.63 (substantial).
  • The kappa value for the intraobserver agreement of the 4 assessors for the surface patterns was 0.70, 0.65, 0.60, and 0.79, and for the prediction of polyp type was 0.87, 0.71, 0.61, 0.81.
  • The accuracy to predict polyp type ranged from 80% to 86% for the 4 assessors in the first reading and from 85% to 91% in the second reading, with every assessor showing an improvement in accuracy in the second reading.
  • LIMITATIONS: A single-center study, with a limited number of polyps.
  • CONCLUSIONS: This initial evaluation showed that the NBI polyp patterns described in our pilot study are reproducible, easy to learn, reasonably accurate, and have the potential for use in daily clinical practice for the real-time differentiation of colon polyps.
  • [MeSH-major] Colonic Polyps / pathology. Colonoscopy / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2009 Mar;69(3 Pt 2):723-5 [19251017.001]
  • (PMID = 19251016.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Mai PL, Korde L, Kramer J, Peters J, Mueller CM, Pfeiffer S, Stratakis CA, Pinto PA, Bratslavsky G, Merino M, Choyke P, Linehan WM, Greene MH: A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report. J Med Case Rep; 2007 Mar 28;1:9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A possible new syndrome with growth-hormone secreting pituitary adenoma, colonic polyposis, lipomatosis, lentigines and renal carcinoma in association with familial testicular germ cell malignancy: A case report.
  • BACKGROUND: Germ-cell testicular cancer has not been definitively linked to any known hereditary cancer susceptibility disorder.
  • His evaluation as part of an etiologic study of familial testicular cancer revealed multiple colon polyps (adenomatous, hyperplastic, and hamartomatous) first found in his 50 s, multiple lipomas, multiple hyperpigmented skin lesions, left kidney cancer diagnosed at age 64, and a growth-hormone producing pituitary adenoma with associated acromegaly diagnosed at age 64.
  • Alternatively, this family's phenotype might represent a novel neoplasm susceptibility disorder.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):629-31 [15799199.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:108-15 [15761242.001]
  • [Cites] Am J Gastroenterol. 2005 Feb;100(2):476-90 [15667510.001]
  • [Cites] Dig Dis Sci. 2004 Apr;49(4):662-6 [15185875.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):363-71 [15172357.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):984-92 [12569597.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Dec;86(12):5658-71 [11739416.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Hum Mol Genet. 2006 Feb 1;15(3):443-51 [16407372.001]
  • (PMID = 17411461.001).
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CP / N02CP11019
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1847830
  •  go-up   go-down


43. Hsu HH, Cheng SF, Wu CC, Chu CH, Weng YJ, Lin CS, Lee SD, Wu HC, Huang CY, Kuo WW: Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner. Chin J Physiol; 2006 Apr 30;49(2):110-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner.
  • Epidemiologic studies reported that the prevalence of hereditary non-polyposis colon cancer (HNPCC) in male is about 1.5-fold higher than that in female.
  • Patients that received E2 replacement therapy were found to have a reduction in the incidence of colon adenoma and carcinoma.
  • [MeSH-major] Apoptosis. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Estrogen Receptor beta / metabolism. Signal Transduction. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Chin J Physiol. 2006 Jun 30;49(3):167
  • (PMID = 16830793.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Estrogen Receptor beta; 0 / Ligands; 0 / Recombinant Proteins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


44. Ukarapol N, Singhavejakul J, Lertprasertsuk N, Wongsawasdi L: Juvenile polyp in Thai children--clinical and colonoscopic presentation. World J Surg; 2007 Feb;31(2):395-8
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile polyp in Thai children--clinical and colonoscopic presentation.
  • BACKGROUND: The aim of this prospective study was to describe the clinical characteristics of colorectal polyp in Thai children.
  • Location, number, characteristics, and histopathology of the polyps were noted.
  • In 20 patients there was a single polyp, 6 had 2-4 polyps, and 6 were diagnosed with polyposis coli.
  • Most of the polyps were located exclusively at the rectum and sigmoid colon.
  • In only 7 cases were the polyps proximal to the rectosigmoid region.
  • This included 6 patients who had polyps beyond the splenic flexure.
  • All were juvenile polyps without evidence of adenomatous changes.
  • Compared to those with isolated polyps, the patients with polyposis coli had a statistically significant incidence of right-sided polyps (P <0.001) and a history of prolapse of the rectal mass (P = 0.006).
  • CONCLUSIONS: Because of the high prevalence of right-sided polyps and the concern about malignant transformation, colonoscopy should be considered as the initial evaluation in children with rectal bleeding.
  • [MeSH-major] Asian Continental Ancestry Group. Colonic Polyps / ethnology. Colonic Polyps / pathology. Colonoscopy. Rectal Diseases / ethnology. Rectal Diseases / pathology
  • [MeSH-minor] Adenomatous Polyposis Coli / complications. Adenomatous Polyposis Coli / ethnology. Adenomatous Polyposis Coli / pathology. Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Prospective Studies. Thailand

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17235457.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Traboulsi EI: Ocular manifestations of familial adenomatous polyposis (Gardner syndrome). Ophthalmol Clin North Am; 2005 Mar;18(1):163-6, x
MedlinePlus Health Information. consumer health - Retinal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular manifestations of familial adenomatous polyposis (Gardner syndrome).
  • Familial adenomatous polyposis (FAP) is a colon cancer predisposition syndrome in which hundreds to thousands of precancerous colonic polyp become evident at a mean age of 16 years (range, 7-36 years).
  • By age 35 years, 95% of patients have polyps.


46. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA: Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers. Cancer Prev Res (Phila); 2009 Nov;2(11):951-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers.
  • Nonsteroidal anti-inflammatory drugs (NSAID) have been highly effective in preventing colon, urinary bladder, and skin cancer preclinically, and also in clinical trials of colon adenoma formation.
  • In the azoxymethane-induced rat colon aberrant crypt foci (ACF) model, naproxen administered at 200 and 400 ppm in the diet reduced mean ACFs in the colon by about 45% to 60%, respectively.
  • These data show that both naproxen and NO-naproxen are effective agents against urinary bladder and colon, but not mammary, carcinogenesis.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NAPROXEN .
  • Hazardous Substances Data Bank. N-NITROSO-N-METHYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6187-92 [3167865.001]
  • [Cites] Trends Mol Med. 2004 Jul;10(7):324-30 [15242680.001]
  • [Cites] J Cell Biochem Suppl. 1992;16G:55-62 [1361589.001]
  • [Cites] Biometrics. 1993 Mar;49(1):259-68 [8513108.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1493-7 [8353834.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4182-8 [8364913.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1464-72 [7882354.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):355-60 [9162301.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Ann Rheum Dis. 2005 Mar;64(3):449-56 [15345500.001]
  • [Cites] N Engl J Med. 2005 Mar 17;352(11):1071-80 [15713944.001]
  • [Cites] Scand J Gastroenterol. 2006 Mar;41(3):264-73 [16497612.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1232-9 [16344269.001]
  • [Cites] Carcinogenesis. 2006 Jun;27(6):1214-21 [16352617.001]
  • [Cites] BMJ. 2006 Jun 3;332(7553):1302-8 [16740558.001]
  • [Cites] Mol Cancer Ther. 2006 Jun;5(6):1530-8 [16818512.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] JAMA. 2006 Oct 4;296(13):1619-32 [16968832.001]
  • [Cites] Mol Cancer Ther. 2007 Jul;6(7):2022-8 [17620432.001]
  • [Cites] Am J Clin Dermatol. 2007;8(4):195-200 [17645375.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5488-96 [17875779.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jan;29(1):1-20 [18158862.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2908-18 [18853980.001]
  • [Cites] Clin Pharmacol Ther. 2009 Feb;85(2):190-7 [18987620.001]
  • [Cites] Trends Pharmacol Sci. 2009 Mar;30(3):112-7 [19230986.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):293-7 [10667579.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5599-602 [11059745.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:137-44 [12628511.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 7):36-44 [15179622.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5270-4 [1913650.001]
  • (PMID = 19892664.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 CN043301; United States / NCI NIH HHS / CN / NCI-CN43301; United States / NCI NIH HHS / CA / N01CN53300; United States / NCI NIH HHS / CN / NCI-CN53300; United States / NCI NIH HHS / CN / N01 CN053300; United States / NCI NIH HHS / CA / N01CN43301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Nitric Oxide Donors; 0 / naproxen-n-butyl nitrate; 3817-11-6 / Butylhydroxybutylnitrosamine; 57Y76R9ATQ / Naproxen; 684-93-5 / Methylnitrosourea; MO0N1J0SEN / Azoxymethane
  • [Other-IDs] NLM/ NIHMS142040; NLM/ PMC2774912
  •  go-up   go-down


47. Yuan B, Jin X, Zhu R, Zhang X, Liu J, Wan H, Lu H, Shen Y, Wang F: Cronkhite-Canada syndrome associated with rib fractures: a case report. BMC Gastroenterol; 2010;10:121
MedlinePlus Health Information. consumer health - Osteoporosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophagogastroduodenoscopy, video capsule endoscopy and colonoscopy revealed various sizes of generalized gastrointestinal polyps.
  • Histological examination of the biopsy specimens obtained from the stomach and the colon showed adenomatous polyp and inflammatory polyp respectively.

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):388-91 [11522989.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):333-42 [11876685.001]
  • [Cites] Expert Opin Pharmacother. 2003 Mar;4(3):385-9 [12614190.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1444-6 [12818298.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):570-2 [18294523.001]
  • [Cites] Medicine (Baltimore). 1982 Sep;61(5):293-309 [7109958.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):537-41 [9434222.001]
  • [Cites] N Engl J Med. 1955 Jun 16;252(24):1011-5 [14383952.001]
  • [Cites] Digestion. 2007;75(2-3):96-7 [17510553.001]
  • [Cites] Digestion. 2004;69(1):57-62 [14755154.001]
  • (PMID = 20955587.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972238
  •  go-up   go-down


48. Romano G, Cocchiara G, Maniaci S, Buscemi G, Calderone F, Gioè FP, Romano M: [The role of colonoscopy in patient follow-up after surgery for colorectal cancer. A retrospective study and review of the literature]. G Chir; 2007 Oct;28(10):399-402
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] L'utilità della colonscopia nel follow-up dei pazienti operati per cancro del colon-retto. Analisi retrospettiva e revisione della letteratura.
  • To improve survival rate after colon or rectum resection for cancer patients should be strictly followed up in order to identify possible local disease relapse or metachronous neoplasia.
  • Nineteen of the patients underwent a left colectomy, 28 an anterior resection, 18 a right colectomy and 3 a resection of the transverse colon.
  • In addition, in 11 cases, there were 3 right colon adenomatous polyps, 2 transverse colon polyps (one villous and the other tubular), 5 descending colon polyps (three tubular and two villous) and 1 tubulo-villous polyp of the rectum.
  • An examination of the data resulting from our own 68 cases shows that, in spite of the fact that no local disease relapse or metachronous neoplasia was observed, the identification of 11 polyps would suggest that the use of colonoscopy in such patients might be the gold standard for early diagnosis of recurrences and new polyps.
  • [MeSH-minor] Aged. Colonic Polyps / diagnosis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17915057.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 55
  •  go-up   go-down


49. Liang JJ, Alrawi S, Tan D: Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma. Int J Clin Exp Pathol; 2008;1(4):317-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nomenclature, molecular genetics and clinical significance of the precursor lesions in the serrated polyp pathway of colorectal carcinoma.
  • Serrated adenomas (SAs) are part of the distinct serrated polyp pathway of colorectal carcinogenesis characterized by microsatellite instability and deficiency in DNA mismatch repair.
  • Sessile SA is a recently recognized lesion that typically presents as a large sessile polyp, but lacks the conventional dysplasia.
  • It is more frequently found on the right side than on the left side of the colon, and is thought to represent an intermediate form in the hyperplastic polyp to sessile SA, traditional SA, and colon cancer sequence.
  • Many terms have been used and are still in use in the literature to describe this lesion, such as "hyperplastic polyposis", "giant hyperplastic polyposis," "large hyperplastic polyps," "hyperplastic-adenomatous polyposis syndrome," "giant hyperplastic polyp," and "mixed epithelial polyp."
  • The purpose of this paper is to review and clarify the confusing nomenclature, and to provide a framework for understanding the genetic alterations and clinical significance of these precursor lesions in the serrated polyp pathway of colorectal caner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2005 Jan;36(1):101-11 [15712188.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1909-16 [10815915.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1318-21 [9812896.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1158-60 [10478680.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3391-400 [9699671.001]
  • [Cites] Gut. 1998 May;42(5):680-4 [9659164.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):417-23 [9130988.001]
  • [Cites] Cell. 1997 Oct 17;91(2):231-41 [9346240.001]
  • [Cites] Gut. 1997 May;40(5):660-3 [9203947.001]
  • [Cites] In Vivo. 1996 May-Jun;10(3):339-43 [8797037.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):748-55 [8608884.001]
  • [Cites] Gut. 1992 Nov;33(11):1508-14 [1452076.001]
  • [Cites] Int J Cancer. 1986 Aug 15;38(2):173-6 [3733258.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):510-5 [6198059.001]
  • [Cites] Am J Surg Pathol. 1984 Jul;8(7):551-6 [6742315.001]
  • [Cites] Gastroenterology. 1974 Mar;66(3):347-56 [4813500.001]
  • [Cites] Gastroenterology. 1973 May;64(5):926-45 [4700419.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Arch Pathol. 1970 Apr;89(4):349-54 [5435674.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1452-9 [15489648.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Jan;22(1):48-53 [16319676.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):380-91 [16191506.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Aug;2(8):398-405 [16130936.001]
  • [Cites] Histopathology. 2005 Jul;47(1):32-40 [15982321.001]
  • [Cites] J Pathol. 2005 May;206(1):62-7 [15751053.001]
  • [Cites] Am J Pathol. 2005 Apr;166(4):1069-75 [15793287.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):825-8 [15326579.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Aug;129(8):449-55 [12884030.001]
  • [Cites] Pathol Int. 2003 May;53(5):277-83 [12713561.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1012-8 [12376501.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):862-76 [12198712.001]
  • [Cites] J Gastroenterol. 2002;37(6):467-70 [12108682.001]
  • [Cites] Am J Pathol. 2002 Feb;160(2):529-36 [11839573.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Am J Clin Pathol. 2005 Mar;123(3):349-59 [15716230.001]
  • (PMID = 18787610.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480541
  • [Keywords] NOTNLM ; Polyp / adenomatous / carcinoma / colon / hyperplastic / sessile serrated adenoma
  •  go-up   go-down


50. Park SY, Kim BC, Shin SJ, Lee SK, Kim TI, Kim WH: Proximal shift in the distribution of adenomatous polyps in Korea over the past ten years. Hepatogastroenterology; 2009 May-Jun;56(91-92):677-81
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proximal shift in the distribution of adenomatous polyps in Korea over the past ten years.
  • BACKGROUND/AIMS: Several reports have suggested a trend of right-side shift of colorectal cancer; however, there were only a few studies on the chronologic changes in the distribution of adenomatous polyps.
  • We aimed to study the changes in the distribution of colorectal adenomatous polyps over the past ten years.
  • Patients who had an adenomatous polyp with a diameter of at least 5mm were included.
  • Of these, patients with a history of colon resection, colorectal cancer, colorectal polyp, inflammatory bowel disease, HNPCC, or familial adenomatous polyposis were excluded.
  • RESULTS: A total of 2,498 patients and 4,591 adenomatous polyps were included in this study.
  • Analysis with respect to number of patients showed significant increases in the proportion of patients with adenomatous polyp on the proximal colon, from 48.5% to 66.3% (p<0.001).
  • Analysis with respect to number of polyps revealed that the proportion of adenomatous polyps on the proximal colon significantly increased from 48.9% to 62.3% (p<0.001).
  • CONCLUSIONS: The proportion of adenomatous polyp on the proximal colon significantly increased over the past 10 years.
  • [MeSH-major] Adenomatous Polyposis Coli / ethnology. Adenomatous Polyposis Coli / pathology. Asian Continental Ancestry Group / statistics & numerical data

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621679.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


51. Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM: Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci U S A; 2008 Sep 9;105(36):13544-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice.
  • We have found that the mTORC1 pathway is activated with increased expression of the mTOR protein in intestinal polyps of the Apc(Delta716) heterozygous mutant mouse, a model for human familial adenomatous polyposis.
  • An 8-week treatment with RAD001 (everolimus) suppressed the mTORC1 activity in these polyps and inhibited proliferation of the adenoma cells as well as tumor angiogenesis, which significantly reduced not only the number of polyps but also their size. beta-Catenin knockdown in the colon cancer cell lines reduced the mTOR level and thereby inhibited the mTORC1 signaling.
  • These results suggest that the Wnt signaling contributes to mTORC1 activation through the increased level of mTOR and that the activation plays important roles in the intestinal polyp formation and growth.
  • Thus, we propose that the mTOR inhibitors may be efficacious for therapy and prevention of colonic adenomas and cancers with Wnt signaling activation.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / metabolism. Intestinal Polyps / metabolism. Intestinal Polyps / prevention & control. Signal Transduction. Transcription Factors / metabolism
  • [MeSH-minor] Adenoma / blood supply. Adenoma / drug therapy. Adenoma / pathology. Animals. Cell Proliferation / drug effects. Everolimus. Female. Male. Mice. Mice, Transgenic. Multiprotein Complexes. Proteins. Sirolimus / analogs & derivatives. Sirolimus / pharmacology. Sirolimus / therapeutic use. Survival Rate. TOR Serine-Threonine Kinases. Wnt Proteins / metabolism


52. Paskett ED, Reeves KW, Pineau B, Albert PS, Caan B, Hasson M, Iber F, Kikendall JW, Lance P, Shike M, Slattery ML, Weissfeld J, Kahle L, Schatzkin A, Lanza E, Polyp Prevention Trial Study Group: The association between cigarette smoking and colorectal polyp recurrence (United States). Cancer Causes Control; 2005 Nov;16(9):1021-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association between cigarette smoking and colorectal polyp recurrence (United States).
  • OBJECTIVE: Although evidence exists linking smoking to precancerous colorectal adenomatous polyps, few studies have examined the association between cigarette smoking and recurrence of colorectal polyps.
  • This association was investigated prospectively with data from the Polyp Prevention Trial.
  • The study was completed by 1872 men and women with presence of adenomas at baseline colonoscopy.
  • Multiple logistic regression analysis was used to examine the association between cigarette smoking and polyp recurrence (adenomatous and hyperplastic) up to four years from baseline.
  • RESULTS: Adenoma recurrence was not related to cigarette smoking.
  • Current smokers had increased odds of hyperplastic polyps at follow-up compared to never smokers (OR 2.88, 95% CI 2.06-4.01).
  • Current smoking was associated with subsequent distal (OR 3.44, 95% CI 2.38-4.95) and rectal (OR 3.53, 95% CI 2.15-5.78) hyperplastic polyps, but not subsequent proximal hyperplastic polyps.
  • Cigarette smoking was associated with subsequent multiple and small size (4 mm) hyperplastic polyps.
  • Significant linear trends were observed between development of subsequent hyperplastic polyps and all smoking variables.
  • CONCLUSIONS: Although no association with recurrent adenomas was observed, cigarette smoking was significantly associated with hyperplastic polyp development, except for those in the proximal colon.
  • This prospective study confirms that cigarette smoking has a significant effect on the development of hyperplastic colorectal polyps.
  • [MeSH-major] Colonic Polyps / pathology. Precancerous Conditions. Smoking / epidemiology
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Aged. Colonoscopy. Epidemiologic Studies. Female. Humans. Hyperplasia / epidemiology. Hyperplasia / pathology. Male. Middle Aged. Recurrence. Risk Assessment. Risk Factors. Surveys and Questionnaires. Time Factors. United States

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184467.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. Kim JH, Lee SY, Kim BK, Choe WH, Kwon SY, Sung IK, Park HS, Jin CJ: Importance of the surrounding colonic mucosa in distinguishing between hyperplastic and adenomatous polyps during acetic acid chromoendoscopy. World J Gastroenterol; 2008 Mar 28;14(12):1903-7
Hazardous Substances Data Bank. ACETIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of the surrounding colonic mucosa in distinguishing between hyperplastic and adenomatous polyps during acetic acid chromoendoscopy.
  • AIM: To examine the characteristics of colonic polyps, where it is difficult to distinguish adenomatous polyps from hyperplastic polyps, with the aid of acetic acid chromoendoscopy.
  • METHODS: Acetic acid spray was applied to colonic polyps smaller than 10 mm before complete excision.
  • Both pre- and post-sprayed images were shown to 16 examiners, who were asked to interpret the lesions as either hyperplastic or adenomatous polyps.
  • Regression analysis demonstrated that surrounding colonic mucosa was the only factor that was significantly related to accuracy in discriminating adenomatous from hyperplastic polyps (P < 0.001).
  • Accuracy was higher for polyps with linear surrounding colonic mucosa than for those with nodular surrounding colonic mucosa (P < 0.001), but was not related to the shape, location, or size of the polyp.
  • CONCLUSION: The accuracy of predicting histology is significantly related to the pattern of colonic mucosa surrounding the polyp.
  • Making a histological diagnosis of colon polyps merely by acetic acid spray is helpful for colon polyps with linear, regularly patterned surrounding colonic mucosa, and less so for those with nodular, irregularly patterned surrounding colonic mucosa.
  • [MeSH-major] Acetic Acid. Adenomatous Polyps. Colonic Polyps. Endoscopy / methods. Hyperplasia. Intestinal Mucosa

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2003 Jan;57(1):48-53 [12518130.001]
  • [Cites] Endoscopy. 2003 May;35(5):437-45 [12701018.001]
  • [Cites] Ann Surg. 1987 Jun;205(6):659-64 [3592808.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1253-8 [8613016.001]
  • [Cites] Gastrointest Endosc. 1996 Jul;44(1):8-14 [8836710.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1089-93 [15578300.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):687-94 [11979251.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):824-8 [16650546.001]
  • [Cites] World J Gastroenterol. 2006 Apr 21;12(15):2402-5 [16688833.001]
  • [Cites] Gastrointest Endosc. 2006 Jun;63(7):1010-7 [16733118.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Endoscopy. 2006 Jun;38(6):613-6 [16612744.001]
  • [Cites] Gastrointest Endosc. 2006 Jul;64(1):13-6 [16813796.001]
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1416-20 [16552812.001]
  • (PMID = 18350630.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] Q40Q9N063P / Acetic Acid
  • [Other-IDs] NLM/ PMC2700415
  •  go-up   go-down


54. Selcuk H, Korkmaz M, Kanbay M, Tore E, Sumer H, Unal H, Yeloglu O, Gur G, Bilezikci B, Demirhan B, Yilmaz U, Boyacioglu S: Total colonic polyp diameter: a marker for the risk of malignancy? Hepatogastroenterology; 2008 May-Jun;55(84):936-9
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total colonic polyp diameter: a marker for the risk of malignancy?
  • BACKGROUND/AIMS: The correlation of the risk of malignancy with the sum of the diameters of small colonic polyps is unknown, and data regarding this topic are lacking.
  • In this study, the relationship between the sum of the diameters of the total number of colonic polyps and poor histopathologic characteristics was examined.
  • METHODS: A total of 920 neoplastic colon polyps were evaluated in 480 patients.
  • The "total polyp diameter" (i.e. the sum of all polyp diameters identified during colonoscopy), which was calculated in each patient by adding the diameter of each polyp to a sum, was categorized as "small" (<10mm in diameter) or "large" (> or =10mm in diameter).
  • The polyps were further categorized by histopathologic component as "unfavorable" or "favorable" and were divided into 2 groups: group 1 (those identified as carci noma, carcinoma in situ, villous adenoma, and tubulovillous adenoma with a villous component of more than 25%) and group 2 (mixed adenomatous polyps with various degrees of hyperplastic or inflammatory components and adenomas with a tubular component of more than 75%).
  • RESULTS: Large polyps that had a total diameter greater than or equal to 10mm tended to have poor histopathologic characteristics (p<0.05).
  • Polyps generally tended to localize in the left portion of the colon, and malignant polyps or those at risk for malignancy in particular tended to localize in the left colon (p<0.05).
  • CONCLUSIONS: Polypectomy is recommended for patients in whom the sum of the diameter of all colonic polyps exceeds 10mm.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Adenomatous Polyps / pathology. Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Colonoscopy. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18705301.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


55. Jo WS, Bandipalliam P, Shannon KM, Niendorf KB, Chan-Smutko G, Hur C, Syngal S, Chung DC: Correlation of polyp number and family history of colon cancer with germline MYH mutations. Clin Gastroenterol Hepatol; 2005 Oct;3(10):1022-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of polyp number and family history of colon cancer with germline MYH mutations.
  • BACKGROUND & AIMS: Affected individuals with biallelic MYH mutations are believed to display multiple adenomatous polyps without evidence of vertical transmission.
  • Our goal was to determine the detection rate of germline MYH mutations in a high-risk gastrointestinal cancer clinic population by using polyp number as a selection criterion.
  • RESULTS: Among 45 patients with more than 15 adenomatous polyps not diagnosed with familial adenomatous polyposis, 7 (15.6%) had biallelic MYH mutations.
  • Both had young-onset colorectal cancer (age, <50 y) with fewer than 15 polyps.
  • CONCLUSIONS: Most individuals with MYH mutations exhibit multiple adenomatous polyps.
  • [MeSH-major] Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / pathology. DNA Glycosylases / genetics. Mutation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234049.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / mutY adenine glycosylase
  •  go-up   go-down


56. Pickhardt PJ, Schumacher C, Kim DH: Polyp detection at 3-dimensional endoluminal computed tomography colonography: sensitivity of one-way fly-through at 120 degrees field-of-view angle. J Comput Assist Tomogr; 2009 Jul-Aug;33(4):631-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polyp detection at 3-dimensional endoluminal computed tomography colonography: sensitivity of one-way fly-through at 120 degrees field-of-view angle.
  • PURPOSE: To investigate whether increasing the visual field-of-view (FOV) angle at 3-dimensional (3D) endoluminal computed tomography colonography (CTC) from 90 degrees to 120 degrees allows for single pass fly-through examination of the supine and prone views without sacrificing polyp detection.
  • METHODS: Primary 3D endoluminal CTC evaluation using a 120 degree FOV was performed by 2 experienced radiologists on 73 patients harboring 104 colonoscopy-proven polyps measuring 6 mm or larger.
  • RESULTS: All 104 (100%) polyps were detectable with the single-pass 3D evaluation on either the retrograde supine or antegrade prone fly-through, with 86 (82.7%) of 104 polyps seen on both fly-through views.
  • Of the 18 polyps detected on only one of the two 3D endoluminal passes (10 prone, 8 supine), 13 were either submerged under fluid (n = 12) or within a collapsed segment (n = 1); therefore, these were also undetectable on the corresponding 90 degrees bidirectional fly-through.
  • The remaining 5 (4.8%) polyps were located behind a fold, but these polyps were all detectable on the other fly-through in the reverse direction.
  • CONCLUSIONS: Increasing the visual FOV angle to 120 degrees allows for a decrease in the total number of supine and prone 3D endoluminal fly-through passes from 4 to 2 without negatively impacting overall polyp detection.
  • [MeSH-major] Adenocarcinoma / radiography. Adenomatous Polyps / radiography. Colonic Neoplasms / radiography. Colonic Polyps / radiography. Colonography, Computed Tomographic / methods. Imaging, Three-Dimensional / methods. Radiographic Image Enhancement / methods
  • [MeSH-minor] Cohort Studies. Colon / radiography. Contrast Media. Female. Humans. Male. Middle Aged. Observer Variation. Posture. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19638863.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Powers HJ, Hill MH, Welfare M, Spiers A, Bal W, Russell J, Duckworth Y, Gibney E, Williams EA, Mathers JC: Responses of biomarkers of folate and riboflavin status to folate and riboflavin supplementation in healthy and colorectal polyp patients (the FAB2 Study). Cancer Epidemiol Biomarkers Prev; 2007 Oct;16(10):2128-35
Hazardous Substances Data Bank. Riboflavin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Responses of biomarkers of folate and riboflavin status to folate and riboflavin supplementation in healthy and colorectal polyp patients (the FAB2 Study).
  • A double-blind randomized placebo-controlled intervention study (the FAB2 Study) was carried out in healthy controls and patients with colorectal polyps (adenomatous and hyperplastic) to examine effects of folic acid and riboflavin supplements on biomarkers of nutrient status and on putative biomarkers of colorectal cancer risk (DNA methylation and DNA damage; to be reported elsewhere).
  • Ninety-eight healthy controls and 106 patients with colorectal polyps were stratified for the thermolabile variant of methylene tetrahydrofolate reductase, MTHFR C677T, and were randomized to receive 400 microg of folic acid, 1,200 microg of folic acid, or 400 microg of folic acid plus 5 mg of riboflavin or placebo for 6 to 8 weeks.
  • Blood samples and colon biopsy samples were collected for the measurement of biomarkers of folate and riboflavin status.
  • Riboflavin supplement enhanced the response to low-dose folate in people carrying at least one T allele and having polyps.
  • The magnitude of the response in mucosal folate was positively related to the increase in plasma 5-methyl tetrahydrofolate but was not different between the healthy group and polyp patients.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Biomarkers, Tumor / blood. Folic Acid / administration & dosage. Folic Acid / blood. Riboflavin / administration & dosage. Riboflavin / blood

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932361.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tetrahydrofolates; 0LVT1QZ0BA / Homocysteine; 134-35-0 / 5-methyltetrahydrofolate; 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); TLM2976OFR / Riboflavin
  •  go-up   go-down


58. Stănciulea O, Preda C, Herlea V, Popa M, Ulmeanu D, Vasilescu C: [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis]. Chirurgia (Bucur); 2007 Mar-Apr;102(2):215-20
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare indication of cephalic duodenopancreatectomy with total gastrectomy--periampullary carcinoma in moderate form of familial adenomatous polyposis].
  • [Transliterated title] Indicaţie rară de duodenopancreatectomie cefalică cu gastrectomie totală-- adenocarcinom periampular cu polipoză adenomatoasă familială forma atenuată.
  • We present the case of a 52 years old man, with significant familial history, diagnosed with familial adenomatous polyposis-attenuated form, with no clinical and endoscopic surveillance until 2001 when he was admitted for an upper gastrointestinal haemorrhage episode.
  • Upper gastrointestinal scopy revealed duodenal adenomatous polyps and gastric hyperplastic polyps.
  • The histopathological exam revealed duodenal G2 adenocarcinoma pT3N0, and gastric hyperplastic polyps with no signs of dysplasia.
  • In 2002 the patient was admitted for rectal bleeding and colonoscopy showed 2 sigmoid polyps, appropriate for endoscopic removal and a poly-lobate polyp in the transverse colon.
  • March 2003--the patient underwent endoscopic removal for a rectal polyp (histopathological exam: moderate dysplasia).
  • The surgical procedure recommended in patients with attenuated form of familial adenomatous polyposis and suspect periampullary lesions is duodenopancreatectomy.
  • The particularity of the case is the association of total gastrectomy for gastric hyperplastic polyps.
  • [MeSH-major] Adenomatous Polyposis Coli / surgery. Carcinoma / surgery. Duodenal Neoplasms / surgery. Gastrectomy. Neoplasms, Multiple Primary / surgery. Pancreaticoduodenectomy / methods

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615925.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


59. Oh K, Redston M, Odze RD: Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon. Hum Pathol; 2005 Jan;36(1):101-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Support for hMLH1 and MGMT silencing as a mechanism of tumorigenesis in the hyperplastic-adenoma-carcinoma (serrated) carcinogenic pathway in the colon.
  • BACKGROUND: Down-regulation of DNA repair genes has been proposed as an important mechanism of tumorigenesis in some colon cancers.
  • This mechanism has also recently been implicated in the newly postulated hyperplastic polyp-serrated adenoma-carcinoma ("serrated") pathway of carcinogenesis, although this has never been investigated thoroughly.
  • The aim of this study was to evaluate hMLH1, hMSH2, MGMT, as well as MIB-1, p53, and beta-catenin immunoexpression in an uncommon cohort of mixed colonic polyps that contain a combination of hyperplastic and adenomatous features (n = 21), and in some (n = 7), carcinoma as well.
  • DESIGN: The clinical, pathological, and immunophenotypic (hMLH1, hMSH2, MGMT, MIB-1, p53, and beta-catenin) properties of 28 mixed hyperplastic and adenomatous polyps of the colon (7 of which also contained carcinoma within the same lesion) were evaluated for the above immunopeptides in each of the different morphologic areas of the polyps, and the results were compared to traditional hyperplastic polyps, serrated adenomas, and conventional (nonserrated) adenomas.
  • RESULTS: Clinically, most mixed polyps with carcinoma occurred in the ascending colon (86%), and pathologically, the adenomatous component of most mixed polyps was serrated (96%).
  • Mixed polyps, particularly those with carcinoma, showed loss of hMLH1 (33%), MGMT (37%), and even hMSH2 (11%) with significantly higher frequency compared to hyperplastic polyps, conventional adenomas, and serrated adenomas.
  • More specifically, loss of hMLH1 and MGMT were more frequent in epithelium of higher neoplastic grade in mixed polyps.
  • However, hMSH2 loss was only present in the adenoma component and never in the hyperplastic or carcinomatous areas of these polyps.
  • Defects in MIB-1 proliferation indices and p53 were not significantly different among the same epithelial components in each of the polyp groups.
  • However, conventional adenomas showed significantly higher rates of nuclear beta -catenin staining (100%) in comparison to the adenomatous component of mixed polyps (60%).
  • CONCLUSIONS: Loss of hMLH1 and MGMT play a prominent role in the serrated pathway of carcinogenesis in the colon.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Colonic Neoplasms / genetics. Colonic Polyps / genetics. Gene Silencing. Neoplasm Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Carrier Proteins. Cytoskeletal Proteins / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Female. Humans. Hyperplasia / genetics. Hyperplasia / metabolism. Hyperplasia / pathology. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. MutS Homolog 2 Protein. Nuclear Proteins. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Trans-Activators / metabolism. Tumor Suppressor Protein p53 / metabolism. beta Catenin

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712188.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cytoskeletal Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / Tumor Suppressor Protein p53; 0 / beta Catenin; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


60. Khatibzadeh N, Ziaee SA, Rahbar N, Molanie S, Arefian L, Fanaie SA: The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps. J Cancer Res Ther; 2005 Oct-Dec;1(4):204-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps.
  • BACKGROUND: The appropriate application of Endoscopic modalities for polypectomy depends on the likelihood that the adenoma in question harbors invasive cancer.
  • While prior studies have evaluated polyp size and morphology in assessing the risk of malignancy, in recent decay some authorities have paid more attention to dysplasia.
  • All in all, the relative risk of cancer based on polyp distribution in correlation with dysplasia has not been statistically studied which is done in our study.
  • METHODS AND MATERIALS: Between June 2001 and March 2004, the distribution of 130 adenomatous polyps was compared with synchronous invasive or in situ cancer.
  • Factors such as Patient age, Patients gender, location of lesion, size of polyp, histological subtype of adenoma on biopsy, degree of dysplasia, synchronous cancer, color of polyp, and number of polyps were included in the data collection.
  • CONCLUSION: Lesions greater than 1 cm in diameter with high-grade dysplasia after splenic flexure should be managed as presumptive malignancies with segmental colon resection.
  • [MeSH-major] Adenomatous Polyps / pathology. Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998654.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


61. Saini SD, Kim HM, Schoenfeld P: Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a meta-analysis and systematic review. Gastrointest Endosc; 2006 Oct;64(4):614-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of advanced adenomas at surveillance colonoscopy in patients with a personal history of colon adenomas: a meta-analysis and systematic review.
  • BACKGROUND: Current guidelines stratify patients with a personal history of adenomas as low risk (ie, 1-2 small [<10 mm] adenomas at index colonoscopy) or high risk (> or =3 small adenomas or advanced adenoma at index colonoscopy) for recurrent advanced adenomas.
  • OBJECTIVE: Our purpose was to perform a meta-analysis about the incidence of advanced adenomas at 3-year surveillance colonoscopy among high- and low-risk patients.
  • Study selection criteria were (1) study design--prospective or registry-based study, (2) study population--patients with a personal history of adenomas, and (3) intervention--completion of surveillance colonoscopy at an interval of > or =2 years.
  • Data were extracted on (1) incidence of advanced adenomas at surveillance colonoscopy, (2) interval between colonoscopies, and (3) risk factors associated with recurrent adenomas.
  • After the validity of study design was assessed and independent, duplicate data extraction was performed from selected trials, summary relative risks (RR) for the incidence of advanced adenomas at 3-year colonoscopy were calculated.
  • Patients with > or =3 adenomas at index colonoscopy were more likely to have recurrent advanced adenomas than were patients with 1 to 2 adenomas: RR 2.52, 95% CI 1.07-5.97.
  • Patients with adenomas with high-grade dysplasia at index colonoscopy were also at increased risk for recurrent advanced adenomas: RR 1.84, 95% CI 1.06-3.19.
  • In the individual studies, increasing size of adenomas and increasing number of adenomas at index colonoscopy were the most commonly reported risk factors associated with recurrent advanced adenomas.
  • CONCLUSION: Few published studies stratify the incidence of advanced adenomas at surveillance colonoscopy according to index colonoscopy findings.
  • In the future, large prospective studies or studies using pooled data from existing randomized controlled trial databases or polyp registries should be used to better define which patients are at low risk for advanced adenoma recurrence.
  • [MeSH-major] Adenoma / epidemiology. Adenoma / pathology. Adenomatous Polyps / epidemiology. Adenomatous Polyps / pathology. Colonic Neoplasms / epidemiology. Colonic Neoplasms / pathology. Colonoscopy. Mass Screening. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Rectal Neoplasms / epidemiology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adenoma, Villous / epidemiology. Adenoma, Villous / pathology. Cell Transformation, Neoplastic / pathology. Evidence-Based Medicine. Follow-Up Studies. Humans. Intestinal Mucosa / pathology. Population Surveillance. Practice Guidelines as Topic. Prospective Studies. Randomized Controlled Trials as Topic. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996358.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K23DK060040-03
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


62. Glazer E, Golla V, Forman R, Zhu H, Levi G, Bodenheimer HC Jr: Serrated adenoma is a risk factor for subsequent adenomatous polyps. Dig Dis Sci; 2008 Aug;53(8):2204-7
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated adenoma is a risk factor for subsequent adenomatous polyps.
  • BACKGROUND: Serrated adenomas (SA) are histologically defined by the presence of both hyperplastic and adenomatous features.
  • These uncommon polyps are thought to play an important role in the development of sporadic colorectal cancers (CRC) with microsatellite instability (MSI).
  • This study was undertaken to define the relationship between SA and the future development of adenomatous polyps.
  • These were matched to controls by age, sex, indication for colonoscopy, polyp type and number and duration of follow-up.
  • Of these, 80 patients (0.5%) with SA were found, and of these SA, 80% were found in the left colon.
  • On follow-up examination four patients (24%) and no controls had adenomatous polyps (P = 0.01).
  • Serrated adenomas appear to be found more commonly in the left colon and in older patients.
  • This study found a significant association between SA and the subsequent development of adenomatous polyps.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Precancerous Conditions / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18320324.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Hwang ST, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Won KH, Jin W: Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps. J Gastroenterol Hepatol; 2010 Mar;25(3):562-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps.
  • BACKGROUND AND AIMS: Metabolic syndrome and insulin resistance are associated with a higher risk of colon cancer.
  • Non-alcoholic fatty liver disease (NAFLD) is regarded as a manifestation of metabolic syndrome in the liver.
  • This investigation was initiated to determine whether NAFLD has a relationship to colorectal adenomatous polyps.
  • We divided the 2917 subjects into the adenomatous polyp group (n = 556) and the normal group (n = 2361).
  • RESULTS: The prevalence of NAFLD was 41.5% in the adenomatous polyp group and 30.2% in the control group.
  • By multiple logistic regression analysis, NAFLD was found to be associated with an increased risk of colorectal adenomatous polyps (odds ratio, 1.28; 95% confidence interval, 1.03-1.60).
  • An increased risk for NAFLD was more evident in patients with a greater number of adenomatous polyps.
  • CONCLUSION: NAFLD was associated with colorectal adenomatous polyps.
  • Further studies are needed to confirm whether NAFLD is a predictor for the development of colorectal adenomatous polyps and cancer.
  • [MeSH-major] Adenomatous Polyps / complications. Colorectal Neoplasms / complications. Fatty Liver / complications

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20074156.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


64. Valls Bautista C, Piñol Felis C, Reñé Espinet JM, Buenestado García J, Viñas Salas J: Telomerase activity and telomere length in the colorectal polyp-carcinoma sequence. Rev Esp Enferm Dig; 2009 Mar;101(3):179-86
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity and telomere length in the colorectal polyp-carcinoma sequence.
  • OBJECTIVE: The role of telomerase activity and telomere length in the adenoma-carcinoma sequence of colon carcinogenesis has not been well established.
  • The objective of this study was to determine telomerase activity and telomere length patterns in patients with adenomatous polyps either associated or not with colorectal cancer, as well as the role of telomeric instability in the adenoma-carcinoma sequence.
  • PATIENTS AND METHODS: We included in the study 14 patients who underwent surgery for colorectal cancer and/or polyps.
  • In 6 of these patients fresh samples of tumor tissue, polyps, and normal mucosa were obtained; in the 8 remaining cases, we collected only polyps and normal mucosa.
  • RESULTS: Telomerase activity was detected in 86% of polyps and 50% of associated normal mucosa.
  • Mean telomerase activity in polyp tissue was 5.85; in the normal mucosa it was 0.58 TPG.
  • Polyps in patients without synchronous cancer had a telomerase activity that was significantly higher (9.4) than in those with cancer (1.1).
  • CONCLUSIONS: Telomerase activity increases in the colorectal adenoma-carcinoma sequence, concurrently with a decrease in telomere length.
  • The presence of synchronous cancer modifies telomerase activity in polyps.
  • [MeSH-major] Colonic Polyps / enzymology. Colonic Polyps / genetics. Colorectal Neoplasms / enzymology. Colorectal Neoplasms / genetics. Telomerase / metabolism. Telomere

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19388798.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


65. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, Gounari F, Lee DM, Zhang G, Glickman JN, Shin K, Rao VP, Poutahidis T, Weissleder R, McNagny KM, Khazaie K: Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A; 2007 Dec 11;104(50):19977-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mast cells are an essential hematopoietic component for polyp development.
  • It is generally agreed that most colon cancers develop from adenomatous polyps, and it is this fact on which screening strategies are based.
  • Here we have used mice conditional for the stabilization of beta-catenin or defective for the adenomatous polyposis coli (APC) gene to reinvestigated the identity and importance of tumor-infiltrating hematopoietic cells in polyposis.
  • We show that, from the onset, polyps are infiltrated with proinflammatory mast cells (MC) and their precursors.
  • Depletion of MC either pharmacologically or through the generation of chimeric mice with genetic lesions in MC development leads to a profound remission of existing polyps.
  • Our data suggest that MC are an essential hematopoietic component for preneoplastic polyp development and are a novel target for therapeutic intervention.


66. Sieber OM, Segditsas S, Knudsen AL, Zhang J, Luz J, Rowan AJ, Spain SL, Thirlwell C, Howarth KM, Jaeger EE, Robinson J, Volikos E, Silver A, Kelly G, Aretz S, Frayling I, Hutter P, Dunlop M, Guenther T, Neale K, Phillips R, Heinimann K, Tomlinson IP: Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut; 2006 Oct;55(10):1440-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation.
  • BACKGROUND: Attenuated familial adenomatous polyposis (AFAP) is associated with germline mutations in the 5', 3', and exon 9 of the adenomatous polyposis coli (APC) gene.
  • METHODS AND RESULTS: We found that colonic polyp number varied greatly among AFAP patients but members of the same family tended to have more similar disease severity.
  • 5' Mutants generally had more polyps than other patients.
  • In common with two previous studies of individual kindreds, we found biallelic changes ("third hits") in some polyps.
  • Most "third hits" left three 20 amino acid repeats (20AARs) on the germline mutant APC allele, with LOH (or proximal somatic mutation) of the wild-type allele; but some polyps had loss of the germline mutant with mutation leaving one 20AAR on the wild-type allele.
  • Not all AFAP polyps appear to need "three hits" however.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Germ-Line Mutation / genetics
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / genetics. Adult. Aged. DNA Mutational Analysis. Exons. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Phenotype. Polymorphism, Single Nucleotide

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2003 Jul 3;22(27):4257-65 [12833148.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] Am J Hum Genet. 1996 Dec;59(6):1193-201 [8940264.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Hum Mutat. 1998;11(6):450-5 [9603437.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Nat Med. 1999 Sep;5(9):1071-5 [10470088.001]
  • [Cites] Hum Genet. 1996 Dec;98(6):727-34 [8931709.001]
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3352-7 [10737795.001]
  • [Cites] Am J Hum Genet. 2000 Sep;67(3):582-90 [10924409.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2954-8 [11867715.001]
  • [Cites] Hum Mol Genet. 2002 Jun 15;11(13):1549-60 [12045208.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8161-6 [12034871.001]
  • [Cites] Gut. 2002 Sep;51(3):420-3 [12171967.001]
  • [Cites] Hum Mol Genet. 1996 Dec;5(12):1921-4 [8968744.001]
  • (PMID = 16461775.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127527198
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  • [Other-IDs] NLM/ PMC1856441
  •  go-up   go-down


67. Mutoh M, Niho N, Wakabayashi K: Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem; 2006 Apr;387(4):381-5
Hazardous Substances Data Bank. PIOGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.
  • Epidemiologically, a high-fat diet is associated with the risk of colon cancer.
  • In addition, serum levels of triglycerides (TGs) and cholesterol have been demonstrated to be positively associated with colon carcinogenesis.
  • We recently found that an age-dependent hyperlipidemic state (high serum TG levels) exists in Apc-deficient mice, an animal model for human familial adenomatous polyposis.
  • Moreover, treatment with a peroxisome proliferator-activated receptor (PPAR) alpha agonist, bezafibrate, or a PPARgamma agonist, pioglitazone, suppressed both hyperlipidemia and intestinal polyp formation in the mice, with induction of LPL mRNA.
  • When given at 400 or 800 ppm in the diet, it suppresses both hyperlipidemia and intestinal polyp formation in Apc-deficient mice, with elevation of LPL mRNA.
  • In conclusion, a decrease in serum lipid levels by increasing LPL activity may contribute to a reduction in intestinal polyp formation with Apc deficiency.
  • PPARalpha and PPARgamma agonists, as well as NO-1886, could be useful as chemopreventive agents for colon cancer.
  • [MeSH-major] Genes, APC. Hyperlipidemias / drug therapy. Intestinal Polyps / prevention & control. Lipoprotein Lipase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606335.001).
  • [ISSN] 1431-6730
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzamides; 0 / Membrane Proteins; 0 / Organophosphorus Compounds; 0 / PPAR alpha; 0 / PPAR gamma; 0 / Thiazolidinediones; 0 / Triglycerides; 133208-93-2 / 4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 3.1.1.34 / Lipoprotein Lipase; X4OV71U42S / pioglitazone; Y9449Q51XH / Bezafibrate
  • [Number-of-references] 30
  •  go-up   go-down


68. Hao CY, Moore DH, Wong P, Bennington JL, Lee NM, Chen LC: Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin Cancer Res; 2005 Feb 15;11(4):1400-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer.
  • PURPOSE: We have shown that the expression of several genes associated with human colon cancer is altered in the morphologically normal colonic mucosa (MNCM) of APC(min) mice and humans with colon cancers.
  • To determine whether these alterations also occur in the MNCM of individuals who have not developed colon cancer but are at high risk of doing so, we measured gene expression in the MNCM of individuals with a family history of colon cancer.
  • METHODS: Expression of 16 genes in the MNCM of 12 individuals with a first-degree relative with sporadic colon cancer and 16 normal controls were measured by quantitative reverse transcription-PCR.
  • Biopsy samples of MNCM were obtained from the ascending, transverse, descending, and rectosigmoid regions of the colon (2-8 biopsy samples were obtained from each region).
  • RESULTS: Relative to normal controls, the expression of several genes, including PPAR-gamma, SAA1, and IL-8 were significantly altered in the macroscopically normal rectosigmoid mucosa from individuals with a family history of colon cancer.
  • CONCLUSIONS: Molecular abnormalities that precede the appearance of adenomatous polyp are present in the MNCM of individuals who have a family history of colon cancer.
  • This observation raises the possibility of screening for individuals who are at an increased risk of developing colon cancer by analysis of gene expression in rectosigmoid biopsy samples.
  • To assess this possibility, prospective studies will be needed to determine whether or not altered gene expression is associated with the subsequent development of adenomatous polyps and/ or colonic carcinomas.
  • [MeSH-major] Colon / metabolism. Colonic Neoplasms / genetics. Gene Expression / genetics. Intestinal Mucosa / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15746039.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-8; 0 / Membrane Proteins; 0 / PPAR delta; 0 / PPAR gamma; 0 / Serum Amyloid A Protein; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


69. Mandir N, Goodlad RA: Conjugated linoleic acids differentially alter polyp number and diameter in the Apc(min/+) mouse model of intestinal cancer. Cell Prolif; 2008 Apr;41(2):279-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conjugated linoleic acids differentially alter polyp number and diameter in the Apc(min/+) mouse model of intestinal cancer.
  • MATERIALS AND METHODS: The effects of the predominant forms of CLA, namely the c9t11 and t10c12 isomers, or a mixture of these on polyp development, were investigated in the Apc(Min/+) mouse.
  • Crypt fission was increased in the middle small intestine by the t10c12 diet while colonic weight was reduced by c9t11 provision and crypts were 20% shorter.
  • The t10c12 and the mixture significantly reduced polyp number in the proximal small intestine but they increased polyp diameter in the middle and distal small intestine, to an extent that the polyp burden was significantly increased at these sites.
  • All CLAs significantly reduced polyp number in the colon, but the mixture significantly increased polyp diameter in the colon.
  • CONCLUSION: Increased polyp diameter associated with t10c12 diet and especially with the mixture is a cause of concern, as this is the commercially available form.
  • The naturally occurring isomer, c9t11 decreased colonic polyp number and did not increase diameter, suggesting that this natural isomer is the most likely to be protective.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Intestinal Neoplasms / prevention & control. Intestinal Polyps / drug therapy. Linoleic Acids, Conjugated / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336472.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Linoleic Acids, Conjugated; 0 / beta Catenin; 0 / cis-9, trans-11-conjugated linoleic acid; 0 / trans-10,cis-12-conjugated linoleic acid
  •  go-up   go-down


70. Schoen RE, Weissfeld JL, Pinsky PF, Riley T: Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy. Gastroenterology; 2006 Dec;131(6):1683-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Yield of advanced adenoma and cancer based on polyp size detected at screening flexible sigmoidoscopy.
  • BACKGROUND & AIMS: Observational screening of the colon with subsequent referral for colonoscopy raises questions about the threshold of polyp size that necessitates referral.
  • To examine the yield at colonoscopy when a given size lesion is observed, we assessed the yield of advanced adenoma and cancer at colonoscopy based on the size of the abnormality detected at flexible sigmoidoscopy (FSG).
  • RESULTS: Subsequent colonoscopy was performed on 10,850 subjects (60.4% male; mean age, 62.9 years) with a polyp visualized on screening FSG.
  • For women with a polyp 0.5-0.9 cm on FSG (n = 1426), the yield in the distal colon on colonoscopy was 0.6% for cancer (number needed to screen [NNS] = 166) and 14.5% for advanced adenoma (NNS = 7).
  • In men (n = 2183), the yield was 0.7% (NNS = 142) for cancer and 15.9% (NNS = 6) for advanced adenoma.
  • Among persons with polyps 0.5-0.9 cm identified on FSG, 5.5% (198/3609) had distal advanced adenomas that measured <1.0 cm but had villous histology or high-grade dysplasia, and 9.9% (357/3609) had adenomas > or =1 cm.
  • CONCLUSIONS: The yield for a distal advanced adenomatous lesion when a polyp 0.5-0.9 cm is observed at FSG is substantial and is due to the presence of advanced histology in polyps <1 cm and to detection of polyps that measure > or =1.0 cm on colonoscopy.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology. Colonic Polyps / pathology. Sigmoidoscopy / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastroenterology. 2006 Dec;131(6):2006-9 [17188963.001]
  • (PMID = 17188959.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN2551
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


71. Cleary SP, Kim H, Croitoru ME, Redston M, Knight JA, Gallinger S, Gryfe R: Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk. Dis Colon Rectum; 2008 Oct;51(10):1467-73; discussion 1473-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Missense polymorphisms in the adenomatous polyposis coli gene and colorectal cancer risk.
  • PURPOSE: Whereas truncating germline mutations of the adenomatous polyposis coli (APC) gene give rise to familial adenomatous polyposis, missense polymorphisms of APC may confer a weaker risk for colorectal cancer.
  • METHODS: We sequenced the entire open reading frame of the APC gene and tested for two common MYH mutations in a population-based series of patients with colorectal cancer and 5 to 99 adenomas.
  • Missense adenomatous polyposis coli alterations identified in this colorectal cancer multiple-polyp population were analyzed in a population-based series of patients with colorectal cancer and healthy control subjects.
  • RESULTS: Germline APC or mutY human homologue (MYH) alterations were identified in 16 of 39 colorectal cancer-multiple polyp patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2000 Feb 28;149(1-2):203-6 [10737725.001]
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2215-21 [11001924.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):181-6 [11135435.001]
  • [Cites] Chronic Dis Can. 2000;21(2):81-6 [11007659.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1000-4 [11221825.001]
  • [Cites] Eur J Cancer. 2001 Mar;37(4):499-502 [11267860.001]
  • [Cites] Gastroenterology. 2001 Aug;121(2):282-301 [11487538.001]
  • [Cites] Br J Cancer. 2001 Aug 17;85(4):523-6 [11506490.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7616-22 [11606402.001]
  • [Cites] Ann Epidemiol. 2002 Jan;12(1):27-33 [11750237.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):25-6 [11743581.001]
  • [Cites] Am J Epidemiol. 2002 Aug 15;156(4):300-10 [12181099.001]
  • [Cites] Genet Test. 2002 Winter;6(4):313-7 [12537656.001]
  • [Cites] Lancet. 2003 Jul 5;362(9377):39-41 [12853198.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1023-8 [14578138.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):146-9 [14744747.001]
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):550-7 [15122587.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463-7 [271968.001]
  • [Cites] FEBS Lett. 1978 Mar 1;87(1):107-10 [631324.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):533-7 [2841598.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4055-7 [1319838.001]
  • [Cites] Ann Hum Genet. 1992 May;56(Pt 2):99-103 [1503398.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Cell. 1993 Dec 3;75(5):951-7 [8252630.001]
  • [Cites] J Med Genet. 1995 Jul;32(7):568-71 [7562975.001]
  • [Cites] Nucleic Acids Res. 1996 Jan 1;24(1):121-4 [8594558.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Feb;15(2):122-8 [8834176.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Med Genet. 1996 Oct;33(10):814-9 [8933332.001]
  • [Cites] Nucleic Acids Res. 1998 Jan 1;26(1):269-70 [9399850.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Aug;22(4):257-67 [9669663.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10722-7 [9724771.001]
  • [Cites] J Med Genet. 1999 Jan;36(1):14-20 [9950360.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2322-6 [10051640.001]
  • [Cites] Hum Mol Genet. 1999 May;8(5):889-97 [10196379.001]
  • [Cites] J Natl Cancer Inst. 2004 Nov 3;96(21):1631-4 [15523092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 9;101(45):15992-7 [15520370.001]
  • (PMID = 18612690.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA074783-06; United States / NCI NIH HHS / CA / CA074783-06; United States / NCI NIH HHS / CA / CA074783-07; United States / NCI NIH HHS / CA / U01 CA074783; United States / NCI NIH HHS / CA / U01 CA074783-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS139709; NLM/ PMC2768068
  •  go-up   go-down


72. Muthunayagam NP, Rohrer JE, Wright SE: Correlation of iron and colon adenomas. Gastroenterol Clin Biol; 2009 May;33(5):435-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of iron and colon adenomas.
  • BACKGROUND AND OBJECTIVE: Better colon cancer screening guidelines are needed.
  • This study was conducted to explore the relationship between serum transferrin saturation (as iron is a potential carcinogen) and presence of colon adenomas.
  • This may aid to evolve better colon cancer screening guidelines.
  • The adjusted odds ratio, derived from multiple logistic regression analysis, was used to measure the association between transferrin saturation and colon adenomas.
  • The adjusted odds ratio, for predicting the presence of polyp in those patients with transferrin saturation above the median was 10.9 (CI 4.0-29.5, P<0.001).
  • A one percent increase in transferrin saturation was associated with a 1.07 increase the odds of adenoma (CI 1.03-1.11, P<0.001).
  • CONCLUSIONS: Iron levels are directly linked to presence of colon polyps, and might help in evolving better screening guidelines.
  • [MeSH-major] Adenoma / blood. Adenoma / etiology. Colonic Neoplasms / blood. Colonic Neoplasms / etiology. Iron Overload / complications. Transferrin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19144479.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Transferrin
  •  go-up   go-down


73. Mandir N, Englyst H, Goodlad RA: Resistant carbohydrates stimulate cell proliferation and crypt fission in wild-type mice and in the Apc(Min/+) mouse model of intestinal cancer, association with enhanced polyp development. Br J Nutr; 2008 Oct;100(4):711-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistant carbohydrates stimulate cell proliferation and crypt fission in wild-type mice and in the Apc(Min/+) mouse model of intestinal cancer, association with enhanced polyp development.
  • Fermentation of carbohydrates in the colon can stimulate cell proliferation and could thus be a cancer risk.
  • The effects of resistant carbohydrates, i.e. those not digested and absorbed in the small intestine, on cell proliferation, crypt fission and polyp development were investigated in wild-type and adenomatous polyposis coli multiple intestinal neoplasia (Apc(Min/+)) mice.
  • Tissue from all mice was used to measure cell proliferation and crypt fission and tissue from the Apc(Min/+) mice was scored for polyp number and tumour burden.
  • The Apc(Min/+) mice had elevated cell proliferation and crypt fission in the distal small intestine and colon and these were increased by the resistant carbohydrates.
  • Bran or apple pomace significantly increased polyp number in the proximal third of the small intestine.
  • Apple pulp more than doubled polyp number throughout the small bowel (99.2 (SEM 11.1) v. 40.0 (SEM 8.2), P<0.004).
  • Bran and apple pomace increased polyp diameter and hence burden in the colon by 243 and 150 %, respectively (P<0.05).
  • In conclusion, both types of resistant carbohydrates increased polyp number and tumour burden and this was associated with elevated epithelial cell proliferation and crypt fission.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Colon. Dietary Fiber / administration & dosage. Intestinal Mucosa / pathology. Intestinal Polyps / pathology. Intestine, Small

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Nutr. 2008 Oct;100(4):693-4 [18307832.001]
  • (PMID = 18279550.001).
  • [ISSN] 1475-2662
  • [Journal-full-title] The British journal of nutrition
  • [ISO-abbreviation] Br. J. Nutr.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


74. Liu ES, Ye YN, Shin VY, Wu WK, Wong BC, Cho CH: Interaction of cigarette smoking with cyclooxygenase-2 on ulcerative colitis-associated neoplasia in mice. Cancer Invest; 2007 Dec;25(8):750-7
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The interactions of cigarette smoking with COX-2 on colitis and colitis-associated adenoma formation were studied.
  • Results indicated that CS did not alter acute colonic inflammation.
  • Chronic SC236 treatment abolished the promoting effect of CS on colonic adenoma formation, via suppression of COX-2- and VEGF-mediated proliferation and angiogenesis, and reversed bcl-2-mediated inhibition of apoptosis by CS.
  • [MeSH-major] Adenoma / etiology. Colitis, Ulcerative / complications. Colonic Neoplasms / etiology. Cyclooxygenase 2 / physiology. Pyrazoles / therapeutic use. Smoking / adverse effects. Sulfonamides / therapeutic use

  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18058473.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide; 0 / Pyrazoles; 0 / Sulfonamides; 9042-14-2 / Dextran Sulfate; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


75. Beaton MD, Taylor B, Driman D, Ainsworth P, Adams PC: Colonic interposition in a woman with attenuated familial adenomatosis polyposis: does the location of the colon affect polyp formation? Can J Gastroenterol; 2008 Jul;22(7):634-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic interposition in a woman with attenuated familial adenomatosis polyposis: does the location of the colon affect polyp formation?
  • Attenuated familial adenomatous polyposis (AFAP) is a rare but well-established cause of colorectal carcinoma and multiple polyps.
  • During infancy, the patient underwent surgical correction of esophageal atresia with colonic interposition.
  • While she had developed adenomatous polyps in her native cecum, there was no evidence of polyps or cancer in the segment of large intestine interposed between her upper esophagus and stomach.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Colonic Polyps / pathology

  • Genetic Alliance. consumer health - Familial Polyposis.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 1999 Dec;45(6):829-33 [10562580.001]
  • [Cites] Transl Res. 2007 Sep;150(3):147-9 [17761365.001]
  • [Cites] Surg Today. 2001;31(11):1020-3 [11766074.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Gut. 2002 May;50(5):636-41 [11950808.001]
  • [Cites] Am J Pathol. 2002 Jun;160(6):2253-7 [12057927.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1822-7 [12135043.001]
  • [Cites] J Postgrad Med. 1986 Oct;32(4):206-9 [3585794.001]
  • [Cites] Cancer. 1988 Apr 15;61(8):1563-70 [3349420.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):812-4 [9041176.001]
  • [Cites] Hum Genet. 1997 Oct;100(5-6):601-5 [9341879.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Nutr Cancer. 1998;31(2):111-8 [9770722.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1664-9 [10223558.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6741-6 [17106919.001]
  • [Cites] Tech Coloproctol. 2006 Dec;10(4):287-96 [17115321.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Feb;61(2):153-61 [17064931.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2395-8 [11289103.001]
  • (PMID = 18629394.001).
  • [ISSN] 0835-7900
  • [Journal-full-title] Canadian journal of gastroenterology = Journal canadien de gastroenterologie
  • [ISO-abbreviation] Can. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2661270
  •  go-up   go-down


76. Kitayama J, Tabuchi M, Tsurita G, Ishikawa M, Otani K, Nagawa H: Adiposity and gastrointestinal malignancy. Digestion; 2009;79 Suppl 1:26-32
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our retrospective studies show that hypertriglyceridemia is an independent risk factor for the development of colonic adenoma and nodal metastasis in early gastric and esophageal cancer in men.
  • [MeSH-major] Adenoma / etiology. Adiposity. Carcinoma / etiology. Colorectal Neoplasms / etiology. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19153487.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adiponectin
  •  go-up   go-down


77. Becker JC, Fukui H, Imai Y, Sekikawa A, Kimura T, Yamagishi H, Yoshitake N, Pohle T, Domschke W, Fujimori T: Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer. Scand J Gastroenterol; 2007 Jul;42(7):852-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonic expression of heme oxygenase-1 is associated with a better long-term survival in patients with colorectal cancer.
  • OBJECTIVE: Heme oxygenase-1 (HO-1) has emerged as a crucial mediator of mucosal defense in the gastrointestinal tract.
  • The role of HO-1 in gastrointestinal malignancies, however, remains to be elucidated.
  • The purpose of this study was to analyze HO-1 expression in human colon adenoma and cancer samples.
  • MATERIAL AND METHODS: Fifty-five paraffin-embedded surgical specimens of colorectal cancer and 19 colonic adenoma samples were stained immunhistochemically for HO-1 expression using an anti-HO-1 monoclonal antibody.
  • HO-1 expression was evaluated independently by two different investigators and subsequently correlated to clinical data and patients' life expectancy.
  • RESULTS: Focal HO-1 expression could be documented in 41.8% (23/55) of patients with colorectal cancer.
  • HO-1 expression in colonic adenoma was detectable in 36.8% (7/19) of cases.
  • The rate of lymphatic tumor invasion was significantly lower in colorectal cancer samples expressing HO-1 (p=0.048).
  • Additionally, fewer lymph node metastases were found in colorectal cancer samples with HO-1 expression, but these differences did not reach statistical significance.
  • Kaplan-Meier analysis showed a significantly better survival for colorectal cancer patients with colonic HO-1 expression (p=0.018).
  • CONCLUSIONS: This study demonstrates that colonic HO-1 may be a prognostic marker of colorectal-cancer outcome.
  • [MeSH-major] Adenoma / enzymology. Biomarkers, Tumor / metabolism. Colon / enzymology. Colorectal Neoplasms / enzymology. Heme Oxygenase-1 / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Colorectal cancer 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17558910.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


78. Kaczka A, Kumor A, Pietruczuk M, Małecka-Panas E: [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer]. Pol Merkur Lekarski; 2007 May;22(131):373-5
MedlinePlus Health Information. consumer health - Diabetes Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer].
  • Colon carcinogenesis is a multi-steps process in which many growth factors are involved.
  • In some studies the increased risk of colon cancer development was observed in patients with diabetes mellitus type 2 with accompanying hyperinsulinemia.
  • The aim of the study was to evaluate the serum concentration of insulin, C-peptide and IGF-I in patients with colon adenomas and colorectal cancer.
  • MATERIALS AND METHODS: In 17 patients with colon cancer, 32 patients with colon adenomas and in 12 healthy persons the serum concentration of insulin, C-peptide and IGF-I was determined using ELISA kits.
  • RESULTS: In patients with colon cancer significantly higher serum IGF-I concentration comparing to the control group was observed (85.66 ng/ml vs. 60.96 ng/ml; p < 0.05).
  • In patients with colon adenomatous polyps we also observed higher serum IGF-I concentrations I comparing to the control group (82.1 ng/ml vs. 60.96 ng/ml), in high dysplasia adenomas (84.12 ng/ml vs. 79.67 ng/ml) and in smaller adenomas to 1 cm diameter (97.98 ng/ml vs. 73.28 ng/ml), but the differences were not significant.
  • We also observed higher concentration of C-peptide in patients with low grade dysplasia adenomas (665.24 pmol/l vs. 498.13 pmol/l) and with small polyps (611.51 pmol/l vs. 514.89 pmol/l).
  • There were no differences in serum concentration of IGF-I and C-peptide between patients with tubular and villous adenomas.
  • CONCLUSIONS: IGF-I is probably involved particularly in the early stage of colon carcinogenesis.
  • [MeSH-major] Adenoma / blood. Adenomatous Polyps / blood. C-Peptide / blood. Colonic Polyps / blood. Colorectal Neoplasms / blood. Insulin / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17679371.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / C-Peptide; 0 / Insulin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


79. Kanthan R, Gomez D, Senger JL, Kanthan SC: Endoscopic biopsies of duodenal polyp/mass lesions: a surgical pathology review. J Clin Pathol; 2010 Oct;63(10):921-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic biopsies of duodenal polyp/mass lesions: a surgical pathology review.
  • BACKGROUND AND AIMS: Endoscopic biopsies of duodenal polyp/mass lesions are uncommon surgical pathology specimens.
  • A surgical review with a report on three unusual duodenal polyp/mass lesions is presented.
  • METHODS: A computer-based data search of duodenal polyp/mass lesions was conducted at the Saskatoon Health Region using the Lab Information System from 1996 to 2009.
  • RESULTS: The three index cases included duodenal polyp/mass lesions, which on primary analysis were diagnosed as 'poorly differentiated' carcinomas with some unusual features.
  • 130 duodenal polyp/mass related lesions were identified.
  • 16.3% of the carcinomas were reclassified as metastatic lesions arising from lung, breast, colon and pancreas.
  • The remainder were predominantly adenomatous (14.9%) and inflammatory (13.8%) in origin.
  • CONCLUSIONS: Endoscopic biopsies of duodenal polyp/mass lesions remain an uncommon specimen (0.01% in the authors' surgical pathology practice).
  • Nevertheless, accurate identification of the exact pathology, even in 'poorly differentiated' high-grade carcinomas is advocated, as metastatic lesions will require specific treatment plans in conjunction with treatment of their primary tumour.
  • [MeSH-major] Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Intestinal Polyps / pathology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876326.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL, Wang YH: Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol; 2005 Jun 21;11(23):3632-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege.
  • AIM: To detect the expression of Fas ligand (FasL) in colon cancer tissues and cell lines and analyze the function of FasL-expressing colon cancer cells in inducing Fas-sensitive T lymphocyte apoptosis.
  • METHODS: Ninety surgically resected colon cancer tissues and 15 hepatic metastasis specimens were investigated by immunohistochemical method with normal colon mucosa and colon adenoma as control.
  • FasL expression of 4 colon cancer cell lines, SW620, Lovo, LS-174T and SW1116, were detected by Western blotting assay.
  • The function of FasL expressed on colon cancer cells was determined by coculture assay with Jurkat T lymphocytes, the apoptotic rate of which was detected by flow cytometry assay.
  • RESULTS: Fifty-six (62.22%) cases of all the 90 colon cancer tissues and all (100%) the liver metastasis specimens expressed FasL, significantly higher than normal colon mucosa and colonic adenoma.
  • Higher expression of FasL was found in more advanced stage of colon cancer and in cancer tissues with lymphatic or hepatic metastasis.
  • All the colon cancer cell lines were found to express FasL.
  • CONCLUSION: The expression of FasL is upregulated in colon cancer and the functionally expressed FasL can induce apoptosis of Fas-expressing T lymphocytes.
  • [MeSH-major] Colonic Neoplasms / immunology. Membrane Glycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15962391.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins
  • [Other-IDs] NLM/ PMC4315977
  •  go-up   go-down


81. Phelps RA, Chidester S, Dehghanizadeh S, Phelps J, Sandoval IT, Rai K, Broadbent T, Sarkar S, Burt RW, Jones DA: A two-step model for colon adenoma initiation and progression caused by APC loss. Cell; 2009 May 15;137(4):623-34
ZFIN. ZFIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A two-step model for colon adenoma initiation and progression caused by APC loss.
  • Aberrant Wnt/beta-catenin signaling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate colon adenoma formation.
  • These findings suggest that, following APC loss, CtBP1 contributes to adenoma initiation as a first step, whereas KRAS activation and beta-catenin nuclear localization promote adenoma progression to carcinomas as a second step.
  • Consistent with this model, human FAP adenomas showed robust upregulation of CtBP1 in the absence of detectable nuclear beta-catenin, whereas nuclear beta-catenin was detected in carcinomas.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] EMBO J. 2000 May 15;19(10):2270-9 [10811618.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51581-9 [15358764.001]
  • [Cites] Oncogene. 2004 Dec 16;23(58):9369-80 [15516977.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26565-72 [15899904.001]
  • [Cites] J Biol Chem. 2005 Aug 26;280(34):30490-5 [15967793.001]
  • [Cites] Gene. 2005 Nov 21;361:1-12 [16185824.001]
  • [Cites] Science. 2005 Dec 2;310(5753):1504-10 [16293724.001]
  • [Cites] Genes Dev. 2006 Mar 1;20(5):586-600 [16510874.001]
  • [Cites] EMBO Rep. 2006 Apr;7(4):444-9 [16439994.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):9971-6 [16476742.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2735-45 [16710294.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13409-14 [16938888.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37828-35 [17028196.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4036-41 [17360473.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2469-79 [17363564.001]
  • [Cites] Am J Med Genet A. 2007 Jul 1;143A(13):1472-80 [17551924.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29394-400 [17673467.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9721-30 [17942902.001]
  • [Cites] Science. 2008 Jan 18;319(5861):333-6 [18202290.001]
  • [Cites] Cell. 2008 Apr 18;133(2):340-53 [18423204.001]
  • [Cites] Nat Genet. 2008 May;40(5):600-8 [18372904.001]
  • [Cites] Gastroenterology. 2006 Oct;131(4):1096-109 [17030180.001]
  • [Cites] Cell. 2000 Oct 13;103(2):311-20 [11057903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8683-8 [12072559.001]
  • [Cites] Curr Biol. 2002 Jul 23;12(14):R499-R501 [12176352.001]
  • [Cites] Am J Clin Pathol. 2003 Sep;120(3):418-23 [14502807.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):633-7 [14534590.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):528-35 [15363803.001]
  • [Cites] J Biol Chem. 2004 Oct 8;279(41):43261-72 [15294912.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):293-7 [3587348.001]
  • [Cites] Nature. 1987 May 28-Jun 3;327(6120):298-303 [2438556.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4624-30 [9377578.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1021-6 [9500465.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):15-21 [10072352.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1442-4 [10197610.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3875-9 [10463573.001]
  • [Cites] Dev Cell. 2004 Nov;7(5):677-85 [15525529.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7219-25 [10602475.001]
  • (PMID = 19450512.001).
  • [ISSN] 1097-4172
  • [Journal-full-title] Cell
  • [ISO-abbreviation] Cell
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA073992; United States / NCI NIH HHS / CA / CA116468-03; United States / NCI NIH HHS / CA / CA073992-06A10003; United States / NCI NIH HHS / CA / R01 CA116468-03; United States / NCI NIH HHS / CA / CA96934; United States / NCI NIH HHS / CA / P01 CA073992-06A10003; United States / NCI NIH HHS / CA / R01 CA116468; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / CA / CA116468-04; United States / NCI NIH HHS / CA / CA042014; United States / NCI NIH HHS / CA / P30 CA042014; United States / NCI NIH HHS / CA / R01 CA116468-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / DNA-Binding Proteins; 0 / Peptide Fragments; 0 / Rac1 GTP-binding protein (17-32); 0 / beta Catenin; EC 1.1.- / Alcohol Oxidoreductases; EC 1.1.1.- / C-terminal binding protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / rac1 GTP-Binding Protein; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS102940; NLM/ PMC2706149
  •  go-up   go-down


82. Deutscher N, Bataille F, Hausmann M, Kiessling S, Muller-Newen G, Leeb SN, Herfarth H, Heinrich PC, Schölmerich J, Rogler G: Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int J Colorectal Dis; 2006 Sep;21(6):573-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer.
  • The aim of this study was to investigate the expression profiling of IL-11Ralpha and its downstream signaling cascade in colonic adenoma and carcinoma.
  • MATERIALS AND METHODS: The expression of IL-11Ralpha in normal colonic mucosa, 11 colonic adenomas, and 10 carcinomas was analyzed by immunohistochemistry.
  • RESULTS: Immunohistochemistry revealed significant IL-11-Ralpha expression in epithelial cells of normal colonic mucosa.
  • In contrast, the expression of IL-11-Ralpha in colon adenomas and carcinomas was either absent or only detectable in very few scattered epithelial cells.
  • Densitometric analysis of Western blots confirmed these results, showing a decrease of IL-11Ralpha-protein in cells isolated from adenomas or carcinomas.
  • CONCLUSION: This study demonstrates a decrease of IL-11-Ralpha-protein expression in epithelial cells isolated from colon carcinomas and adenomas compared to normal colonic mucosa and a reduced STAT3 signaling.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Colonic Neoplasms / metabolism. Interleukin-11 Receptor alpha Subunit / biosynthesis. Intestinal Mucosa / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292518.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-11 Receptor alpha Subunit
  •  go-up   go-down


83. Nam JH, Yang CH: [Clinical characteristics and risk factors of colon polyps in gyeongju and pohang area]. Korean J Gastroenterol; 2008 Sep;52(3):142-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and risk factors of colon polyps in gyeongju and pohang area].
  • BACKGROUND/AIMS: The purposes of this study were to investigate various environmental factors for colon polyps and to analyze locoregional clinical characteristics of colon polyps in Gyeongju and Pohang area.
  • METHODS: From October 2005 to September 2006, patients who underwent colonoscopy were analyzed based on their ages, genders, body mass indices (BMI), dietary habits, smoking behaviors, accompaying diseases, and medications as risk factors for the occurrence of colon polyps.
  • Then clinical manifestations, gross appearances and pathologic findings of polyps were investigated.
  • RESULTS: Among 253 patients enrolled, a total of 296 colon polyps were found in 108 patients.
  • The incidence of colon polyps in more than 50-year old patients was 3.2-fold greater compared to less than 50-year old patients.
  • Smoking habits were also significantly associated with the occurence of colon polyps.
  • Among adenomatous polyps, tubulovillous type and moderate to severe dysplasia were frequently observed as the size increased, yet the location of polyps was not significantly associated.
  • CONCLUSIONS: Older age and smoking habit increase the risk of colon polyps.
  • Rectal polyps have less chance to be adenomatous type.
  • The larger the polyp grows, the more likely it to be tubulovillous and dysplastic.
  • [MeSH-major] Colonic Polyps / diagnosis. Colorectal Neoplasms / diagnosis
  • [MeSH-minor] Adenomatous Polyps / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Korea. Male. Middle Aged. Multivariate Analysis. Odds Ratio. Risk Factors. Rural Population. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077510.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


84. Kozu T, Iinuma G, Ohashi Y, Saito Y, Akasu T, Saito D, Alexander DB, Iigo M, Kakizoe T, Tsuda H: Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial. Cancer Prev Res (Phila); 2009 Nov;2(11):975-83
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of orally administered bovine lactoferrin on the growth of adenomatous colorectal polyps in a randomized, placebo-controlled clinical trial.
  • Animal experiments have shown that oral administration of bovine lactoferrin (bLF) exerts anticarcinogenesis effects in the colon and other organs of the rat.
  • The aim of this study was to determine whether oral bLF could inhibit the growth of adenomatous colorectal polyps in human patients.
  • A randomized, double-blind, controlled trial was conducted in 104 participants, ages 40 to 75 years, with polyps <or=5 mm in diameter and likely to be adenomas.
  • Target adenomatous polyps were monitored by colonoscopy.
  • Ingestion of 3.0-g bLF significantly retarded adenomatous polyp growth in participants 63 years old or younger.
  • Removal of adenomatous colorectal polyps is done as a preventative measure against colorectal cancer; however, polyps can be overlooked, and when detected, polypectomy is not always 100% effective in eradicating a polyp.
  • Our study suggests that daily intake of 3.0 g of bLF could be a clinically beneficial adjunct to colorectal polyp extraction.
  • [MeSH-major] Adenomatous Polyps / pathology. Colorectal Neoplasms / pathology. Lactoferrin / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19861543.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Placebos; EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


85. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV: Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res; 2006 Jul 15;66(14):7370-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
  • Preclinical and clinical studies have established evidence that cyclooxygenase-2 (COX-2) inhibitors and statins [hydroxy-3-methylglutaryl CoA reductase (HMGR) inhibitors] inhibit colon carcinogenesis.
  • We assessed the chemopreventive efficacy of atorvastatin (Lipitor) and celecoxib individually or in combination in an animal model of familial adenomatous polyposis.
  • We observed that 100 ppm atorvastatin significantly (P < 0.002) suppressed intestinal polyp formation.
  • As anticipated, 300 ppm celecoxib decreased the rate of formation of intestinal polyps by approximately 70% (P < 0.0001).
  • Importantly, the combination of 100 ppm atorvastatin and 300 ppm celecoxib in the diet suppressed the colon polyps completely and small intestinal polyps by >86% (P < 0.0001) compared with the control group.
  • [MeSH-major] Adenomatous Polyposis Coli / prevention & control. Anticarcinogenic Agents / pharmacology. Heptanoic Acids / pharmacology. Pyrazoles / pharmacology. Pyrroles / pharmacology. Sulfonamides / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CELECOXIB .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16849589.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-94962; United States / NCI NIH HHS / CN / N01-CN-25114
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Cyclooxygenase Inhibitors; 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyrazoles; 0 / Pyrroles; 0 / Sulfonamides; 48A5M73Z4Q / Atorvastatin Calcium; EC 1.1.1.- / Hydroxymethylglutaryl CoA Reductases; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


86. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • The vitamin levels decreased gradually in AD and CRC patients.
  • 8-OxodG increased in leukocytes and urine of CRC and AD patients.
  • 8-OxoGua excision was higher in CRC patients than in controls, in spite of higher frequency of the OGG1 Cys326Cys genotype, encoding a glycosylase with decreased activity. mRNA levels of OGG1 and APE1 increased in CRC and AD patients, which could explain increased 8-oxoGua excision rate in CRC patients.
  • The results suggest that oxidative stress occurs in CRC and AD individuals.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


87. du Toit J, Hamilton W, Barraclough K: Risk in primary care of colorectal cancer from new onset rectal bleeding: 10 year prospective study. BMJ; 2006 Jul 8;333(7558):69-70
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To measure the risk of colorectal cancer and adenoma with new onset rectal bleeding reported to primary care.
  • MAIN OUTCOME MEASURES: Percentage of participants in whom colorectal cancer or colonic adenoma was identified after investigation of the bowel.
  • Of these, 15 (5.7%, 95% confidence interval 3.2% to 9.2%) had colorectal cancer, and 13 (4.9%, 2.6% to 8.4%) had colonic adenoma.
  • CONCLUSIONS: One in 10 patients aged 45 or more with new onset rectal bleeding had colonic neoplasia, so investigation of the bowel should be offered to all such patients, whether or not they have other symptoms.
  • [MeSH-major] Adenoma / etiology. Colorectal Neoplasms / etiology. Gastrointestinal Hemorrhage / etiology. Rectal Diseases / etiology


88. Gonzalez AB, Stafford I, Mancuso P, Carney S: Delivery of a polyp. Obstet Gynecol; 2008 Aug;112(2 Pt 2):488-90
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delivery of a polyp.
  • Although there is overlap between symptoms of colon cancer and normal pregnancy, clinicians should be vigilant identifying those at risk and offer colorectal cancer screening when appropriate.
  • CASES: Three women in their 30s passed or prolapsed adenomatous tissue per rectum during the second stage of labor.
  • [MeSH-major] Colonic Polyps / diagnosis. Delivery, Obstetric. Incidental Findings
  • [MeSH-minor] Adenoma / pathology. Adult. Colon / pathology. Colonic Neoplasms / pathology. Female. Humans. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Childbirth.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18669775.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Zhou JN, Chen SQ, Zhang XM, Zhou X, Zhu M, Feng B, Li JT, Ma GJ, Zhang YY: [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Aug;23(4):388-91
Genetic Alliance. consumer health - Familial Polyposis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A novel APC gene germline mutation in a familial adenomatous polyposis pedigree].
  • OBJECTIVE: To detect the adenomatous polyposis coli (APC) gene germline mutation in the proband and her family members with familial adenomatous polyposis (FAP).
  • This mutation manifested an aggressive form of FAP with early onset of colorectal adenocarcinoma and colonic adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / genetics. Adenomatous Polyposis Coli Protein / genetics. Germ-Line Mutation

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883523.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein
  •  go-up   go-down


90. Ma YM, Wu BP, Xia OD: [Expression and significance of interferon-inducible transmembrane protein-1 gene in Peutz-Jeghers syndrome]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Mar;29(3):541-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To detect the mRNA and protein expression of interferon-inducible transmembrane protein-1 (IFITM1) in Peutz-Jeghers syndrome (PJS) and investigate the role of IFITM1 in the occurrence, development and carcinogenesis of PJS polyps.
  • METHODS: Reverse transcription-PCR was employed to detect the mRNA expression of IFITM1 in 16 PJS polyp samples, adenomatous polyp tissues, colon adenocarcinoma samples, and normal intestinal mucosal tissues.
  • RESULTS: The IFITM1 mRNA expression was detected in all these tissues, and the expression intensity increased in the order of normal intestinal mucosa, PJS polyp, adenomatous polyp, and colon adenocarcinoma (F=92.704, P=0.000).
  • CONCLUSION: The expression level of IFITM1 is associated with the progression of the carcinogenetic process in PJS polyp, and can be used as a sensitive biomarker for diagnosis and prognostic evaluation of PJS.

  • Genetic Alliance. consumer health - Peutz Jeghers syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304549.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / Biomarkers; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / leu-13 antigen
  •  go-up   go-down


91. Levy BT, Daly JM, Luxon B, Merchant ML, Xu Y, Levitz CE, Wilbur JK: The "Iowa get screened" colon cancer screening program. J Prim Care Community Health; 2010 Apr 1;1(1):43-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The "Iowa get screened" colon cancer screening program.
  • OBJECTIVE: To implement a colon cancer screening program for uninsured or underinsured Iowans.
  • Individuals with colonic symptoms or who were up to date with screening were ineligible.
  • Thirty of the 49 (61%) individuals had a colonoscopy, and 20 individuals had at least 1 polyp biopsied.
  • Thirteen individuals had at least 1 tubular adenoma; 2 had adenomas more than 1 cm in diameter, with no colon cancers identified.
  • CONCLUSION: There was high interest in and compliance with colon cancer screening using a FIT among underinsured individuals.
  • Population-based strategies for offering FIT could significantly increase colon cancer screening among disadvantaged individuals, but programs will have to develop sustainable mechanisms to include the necessary organization and address substantial costs of providing mass screening, as well as facilitating and providing colonoscopies for those who test positive.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23804068.001).
  • [ISSN] 2150-1319
  • [Journal-full-title] Journal of primary care & community health
  • [ISO-abbreviation] J Prim Care Community Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; adenomatous polyp / colorectal cancer screening / fecal immunochemical testing / prevention / recruitment strategies / screening program / tubular adenoma / underinsured / uninsured
  •  go-up   go-down


92. Lau PC, Sung JJ: Flat adenoma in colon: two decades of debate. J Dig Dis; 2010 Aug;11(4):201-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat adenoma in colon: two decades of debate.
  • The existence of flat adenomas in the colon is well recognized.
  • Whether they represent a distinct disease with a pathogenetic pathway different from that of the classical adenoma-carcinoma sequence in colorectal tumorigenesis and have higher malignant potential remains a matter of debate.
  • To review the epidemiology, clinical features, detection and management of flat and depressed (non-polypoid) colonic neoplasm, we performed a thorough literature review on studies focusing on the prevalence, histological features, genetics, detection and treatment of flat and depressed (non-polypoid) colonic neoplasm.
  • A high percentage of severe dysplasia in flat colonic adenomas has not been consistently demonstrated.
  • Flat adenomas are found to have a lower incidence of major genetic abnormalities involved in the classical adenoma-carcinoma sequence and that has raised suspicions that they may have a different pathogenesis.
  • More advanced colonoscopic techniques, such as chromoendoscopy, may enhance the detection of small and inconspicuous colonic neoplastic lesions that lack a protruding configuration.
  • It is essential for endoscopists to appreciate the existence and clinical significance of flat and depressed colonic lesions as an important variant of colonic neoplasms so that the goal of reducing colorectal carcinoma incidence by polypectomy can be better achieved.
  • [MeSH-major] Adenoma. Colonic Neoplasms
  • [MeSH-minor] Colonic Polyps / epidemiology. Colonic Polyps / genetics. Colonic Polyps / pathology. Colonic Polyps / therapy. Colonoscopy. Humans. Rectal Neoplasms / epidemiology. Rectal Neoplasms / genetics. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20649732.001).
  • [ISSN] 1751-2980
  • [Journal-full-title] Journal of digestive diseases
  • [ISO-abbreviation] J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Australia
  •  go-up   go-down


93. Mego M, Májek J, Konceková R, Ebringer L, Cierniková S, Rauko P, Kovác M, Trupl J, Slezák P, Zajac V: Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium. Folia Microbiol (Praha); 2005;50(5):443-7
Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramucosal bacteria in colon cancer and their elimination by probiotic strain Enterococcus faecium M-74 with organic selenium.
  • Intraepithelial bacteria were isolated by the gentamicin protection assay (GPA) from biopsy samples obtained at colonoscopy (colon cancer, n = 10 patients; colonic adenoma, n = 20; control group, n = 20; cancer patients without gastrointestinal tract GIT malignancy, n = 10).
  • The number of biopsies with intracellular bacteria was significantly higher in adenoma and carcinoma group than in control group (26 vs. 10%; p = 0.004); in cancer patients without GIT malignancy the difference was nonsignificant. E. faecium M-74 was also administered to 5 patients with colonic adenoma; according to a control colonoscopy the number of biopsies with intracellular bacteria was significantly lower after probiotic administration (48 vs. 16%; p = 0.03).
  • A striking prevalence of intraepithelial bacteria was also showed in patients with large bowel adenoma and carcinoma.
  • The administration of probiotic strain M-74 can thus be considered to be an effective and promising method for elimination of pathogenic bacteria in the case of inflammatory bowel disease and colon cancer.
  • [MeSH-major] Colonic Neoplasms / microbiology. Enterobacteriaceae / isolation & purification. Enterococcus faecium. Intestinal Mucosa / microbiology. Probiotics / administration & dosage
  • [MeSH-minor] Adenoma / microbiology. Adult. Aged. Aged, 80 and over. Biopsy. Female. Humans. Male. Middle Aged. Selenium / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16475505.001).
  • [ISSN] 0015-5632
  • [Journal-full-title] Folia microbiologica
  • [ISO-abbreviation] Folia Microbiol. (Praha)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] H6241UJ22B / Selenium
  •  go-up   go-down


94. Lü BJ, Cui J, Xu J, Zhang H, Luo MJ, Zhu YM, Lai MD: [Bioinformatic analysis of adenoma-normal mucosa SSH library of colon]. Yi Chuan; 2006 Apr;28(4):385-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bioinformatic analysis of adenoma-normal mucosa SSH library of colon].
  • We established a colonic adenoma-normal mucosa suppressive subtraction hybridization (SSH) library in 1999.
  • The nucleic acid analytical software, an integrator of the universal bioinformatics tools including phred, phd2fasta, cross_match, repeatmasker and blast2.0, can blast sequences of differential clones with the downloaded non-redundant nucleotide (NR) database.
  • Both genes were up-regulated in 10 or 9 out of 10 adenomas in comparison with the paired normal mucosa, respectively.
  • The candidate genes in A-N library would be of great significance in disclosing the molecular mechanism underlying in colonic adenoma initiation and progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16606587.001).
  • [ISSN] 0253-9772
  • [Journal-full-title] Yi chuan = Hereditas
  • [ISO-abbreviation] Yi Chuan
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


95. Pap Z, Pávai Z, Dénes L, Kovalszky I, Jung J: An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1. Pathol Oncol Res; 2009 Dec;15(4):579-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An immunohistochemical study of colon adenomas and carcinomas: E-cadherin, Syndecan-1, Ets-1.
  • Our goal was to study the changes in the expression of these molecules during colon carcinoma development and progression.
  • We tested 117 colon adenomas and 149 de novo and ex adenoma carcinomas of the colon, using the Ultravision Polymer system.
  • The positive reaction rate was 100% for E-cadherin, 98.3% for syndecan-1 and 22.4% for Ets-1 in adenomas, while in carcinomas it was 88.5%, 62.4% and 56.3% respectively.
  • We found decreasing expression of E-cadherin and syndecan-1 throughout colon carcinoma progression and an opposite regulation for the Ets-1 protein.
  • De novo carcinomas have lower E-cadherin and syndecan-1 expression, and higher Ets-1 expression compared to ex adenoma carcinomas.
  • [MeSH-major] Adenoma / metabolism. Cadherins / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Proto-Oncogene Protein c-ets-1 / metabolism. Syndecan-1 / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253033.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Proto-Oncogene Protein c-ets-1; 0 / Syndecan-1
  •  go-up   go-down


96. Park YS: [COX-2 inhibitors in inflammatory bowel disease: friends or foes?]. Korean J Gastroenterol; 2007 Dec;50(6):350-5
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • COX-2 is frequently overexpressed in colonic adenoma and carcinoma.
  • Specific inhibitors of COX-2 have been shown to induce apoptosis in tumor cells and to inhibit tumor growth in animal models and in humans.
  • In a recent study, powerful chemopreventive ability of selective COX-2 inhibitor was observed in colitis-related colon carcinogenesis in mouse model.
  • But it was reported that even selective COX inhibitors aggravated the DSS-induced colonic inflammation.
  • It is assumed that endogenous PGs are involved in the mucosal defense against DSS-induced colonic ulcerations which are produced by COX-1 at early phase and by COX-2 at late phase.
  • Long-term use of COX-2 inhibitors for the chemoprevention of colitic cancer is needed to define their mechanism of action, that reduce side effects and have specific tumor target.
  • [MeSH-minor] Animals. Colonic Neoplasms / diagnosis. Cyclooxygenase 1 / metabolism. Cyclooxygenase 2 / metabolism. Humans. Mice. Models, Animal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18159171.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2
  • [Number-of-references] 59
  •  go-up   go-down


97. Agostini M, Tibiletti MG, Lucci-Cordisco E, Chiaravalli A, Morreau H, Furlan D, Boccuto L, Pucciarelli S, Capella C, Boiocchi M, Viel A: Two PMS2 mutations in a Turcot syndrome family with small bowel cancers. Am J Gastroenterol; 2005 Aug;100(8):1886-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor family history of a patient with cafè-au-lait spots (CALS) and early onset adenomas, duodenal cancer, and glioblastoma was positive for colonic adenoma (mother), jejunal (maternal grandfather), lung (father), and colorectal (paternal uncle) cancers.
  • Our findings point out the association between PMS2 and TS, and support the hypothesis that patients with a few polyps, small bowel tumors with a very early onset, glioblastoma, and CALS should be considered as a variant of hereditary nonpolyposis colorectal cancer.

  • Genetic Alliance. consumer health - Turcot syndrome.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16144131.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / DNA-Binding Proteins; 0 / Neoplasm Proteins; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


98. Ashktorab H, Belgrave K, Hosseinkhah F, Brim H, Nouraie M, Takkikto M, Hewitt S, Lee EL, Dashwood RH, Smoot D: Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci; 2009 Oct;54(10):2109-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma.
  • Chromatin remodeling and activation of transcription are important aspects of gene regulation, but these often go awry in disease progression, including during colon cancer development.
  • We investigated the status of global histone acetylation (by measuring H3, H4 acetylation of lysine residues, which also occur over large regions of chromatin including coding regions and non-promoter sequences) and expression of histone deacetylase 2 (HDAC2) in colorectal cancer (CRC) tissue microarrays using immunohistochemical staining.
  • Specifically, HDAC2 and the acetylation of histones H4K12 and H3K18 were evaluated in 134 colonic adenomas, 55 moderate to well differentiated carcinomas, and 4 poorly differentiated carcinomas compared to matched normal tissue.
  • HDAC2 nuclear expression was detected at high levels in 81.9%, 62.1%, and 53.1% of CRC, adenomas, and normal tissue, respectively (P = 0.002).
  • HDAC2 expression was correlated significantly with progression of adenoma to carcinoma (P = 0.002), with a discriminative power of 0.74, when comparing cancer and non-cancer cases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Aug;20(15):5540-53 [10891493.001]
  • [Cites] Lung Cancer. 2008 Jan;59(1):24-31 [17854949.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Curr Opin Oncol. 2001 Nov;13(6):477-83 [11673688.001]
  • [Cites] J Cell Sci. 2002 Feb 15;115(Pt 4):689-98 [11865025.001]
  • [Cites] Nature. 2002 May 23;417(6887):455-8 [12024216.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1817-23 [12087472.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):377-82 [12385581.001]
  • [Cites] Chem Biol. 2002 Nov;9(11):1167-73 [12445767.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7213-8 [12499261.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:220-31 [12724227.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35775-80 [12837748.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 11;101(19):7398-403 [15123805.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12):5106-18 [15169878.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):1-16 [10825229.001]
  • [Cites] J Assoc Acad Minor Phys. 1999;10(3):59-67 [10826011.001]
  • [Cites] Cancer. 1980 Mar 15;45(5 Suppl):1185-92 [7357511.001]
  • [Cites] Cell. 1997 Aug 22;90(4):595-606 [9288740.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] J Pathol. 2005 Jan;205(1):65-73 [15586362.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):391-400 [15765097.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2684-9 [15805266.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1262-6 [15988529.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):396-401; discussion 401 [16863736.001]
  • [Cites] Methods Enzymol. 2006;410:400-15 [16938563.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2007 Feb 23;128(4):669-81 [17320505.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2685-92 [17363589.001]
  • [Cites] Semin Cancer Biol. 2007 Oct;17(5):363-9 [17555985.001]
  • [Cites] Virchows Arch. 2007 Oct;451(4):763-9 [17674041.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4358-64 [17906200.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • (PMID = 19057998.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA122959; United States / NCI NIH HHS / CA / CA122959-02; United States / NCI NIH HHS / CA / R01 CA122959-02; United States / PHS HHS / / A102681; United States / NCI NIH HHS / CA / R01 CA122959
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ NIHMS118762; NLM/ PMC2737733
  •  go-up   go-down


99. Al-Daraji WI, Abdellaoui A, Salman WD: Osseous metaplasia in a tubular adenoma of the colon. J Clin Pathol; 2005 Feb;58(2):220-1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous metaplasia in a tubular adenoma of the colon.
  • Flexible sigmoidoscopy revealed a 1.5 cm polyp 30 cm from the anus.
  • The polyp was removed during the sigmoidoscopy by electrocautery and sent for histological examination.
  • The polyp was a tubular adenoma with mild dysplasia.
  • The adenoma contained numerous foci of metaplastic bone.
  • This is the first case of osseous metaplasia in a tubular adenoma of the colon to be reported.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Ossification, Heterotopic / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1981 Aug;27(3):198-9 [7297837.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):556-8 [10868462.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1968 Nov;104(3):561-5 [5687904.001]
  • [Cites] J Can Assoc Radiol. 1962 Dec;13:135-9 [13960743.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):86-8 [2492256.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jan;118(1):64-5 [8285834.001]
  • [Cites] Am J Pathol. 1955 Jan-Feb;31(1):73-91 [13218132.001]
  • [Cites] Ann Pathol. 1988;8(1):64-6 [3134902.001]
  • (PMID = 15677548.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770563
  •  go-up   go-down


100. Veeriah S, Miene C, Habermann N, Hofmann T, Klenow S, Sauer J, Böhmer F, Wölfl S, Pool-Zobel BL: Apple polyphenols modulate expression of selected genes related to toxicological defence and stress response in human colon adenoma cells. Int J Cancer; 2008 Jun 15;122(12):2647-55
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apple polyphenols modulate expression of selected genes related to toxicological defence and stress response in human colon adenoma cells.
  • The purpose of this study was to investigate whether polyphenols from apples modulate expression of genes related to colon cancer prevention in preneoplastic cells derived from colon adenoma (LT97).
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Flavonoids / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Malus / chemistry. Phenols / pharmacology. Precancerous Conditions / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18351577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down






Advertisement